[go: up one dir, main page]

TW200900066A - Quinolone medical composition containing alcohols - Google Patents

Quinolone medical composition containing alcohols Download PDF

Info

Publication number
TW200900066A
TW200900066A TW097109983A TW97109983A TW200900066A TW 200900066 A TW200900066 A TW 200900066A TW 097109983 A TW097109983 A TW 097109983A TW 97109983 A TW97109983 A TW 97109983A TW 200900066 A TW200900066 A TW 200900066A
Authority
TW
Taiwan
Prior art keywords
group
carbon atoms
atom
amine
alkyl
Prior art date
Application number
TW097109983A
Other languages
Chinese (zh)
Inventor
Yoshihiro Hasegawa
Yoji Nishimoto
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of TW200900066A publication Critical patent/TW200900066A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention provides a steady aqueous composition containing quinolone. A steady aqueous composition containing quinolone is obtained by controlling the formation of unsoluble microcorpuscle and/or the analogous material through adding alcohols, more desirably a alcohol of carbons. number from one to three.

Description

200900066 » 九、發明說明: 【發明所屬之技術領域】 本發明爲有關添加醇類來改善安定性之含有喹喏酮之水 性製劑及含有喹喏酮之水性製劑之安定化方法。 【先前技術】 就優異抗菌藥之喹喏酮化合物,作爲劑型選擇水性製劑 時,有時發生褐色凝膠狀之不溶性微粒子。水性液劑中之 不溶性微粒子數,除限度値被規定而須規定値以下之外, ^: 以不發生較佳。 關於不溶性微粒子之發生抑制,於ozagrel鈉注射液添加 - 有機酸、胺基酸、聚胺基羧酸或多價醇來抑制不溶性微粒 ' 子之生成之報告(專利文獻1及2)。又於喹喏酮羧酸系之 抗菌劑添加糖醇,來抑制保存中之含量低下及不溶性微粒 ' 子之增加,而改善安定性(專利文獻3)。但於這些方法有 不溶性微粒子之生成抑制效果不充分之場合。 於含有醇類之水性製劑,以difloxacin爲有效成分之注射 r ; " 劑中,添加L-精胺酸、丙二醇、乙醇及苄醇,來減輕投與 部位之組織損傷之報告(專利文獻4)。但抑制生成不溶性 微粒子之效果等水性製劑之安定化效果依然未知。 【專利文獻1】 特開200 1 -3 16265公報 【專利文獻2】 特開2003-63963公報 【專利文獻3】 特開2006- 1 5 1 808公報 【專利文獻4】 美國專利第6872723號 【發明內容】 200900066 (發明欲解決之課題) 本發明之目的爲獲得更安定之含有喹喏酮之水性製劑。 (解決課題之手段) 本發明者爲致力檢討由各種添加劑之不溶性微粒子之抑 制。結果發現,添加濃甘油、無水乙醇及丙二醇等醇類, 則不溶性微粒子數減少。更發現醇類之添加不僅減低不溶 性微粒子,也有抑制類縁物質之生成之效果,終於完成本 發明。 C' 也即本發明爲有關含有喹喏酮化合物及醇之安定之水性 製劑。 本發明更有關於含有喹喏酮化合物之水溶液添加醇爲特 徵之含有喹喏酮之水性製劑之安定化方法。 ' (發明之效果) 本發明之添加醇之水性製劑爲由醇類之添加而抑制不溶 性微粒子之發生,改善保存安定性。且醇類之添加也可抑 制類縁物質之生成,得改善保存安定性之安定之含有喹喏 酮之水性製劑。 【實施方式】 (實施發明之最佳形態) 本發明爲有關含有作爲有效成分之喹喏酮化合物,作爲 安定化成分之醇類之水性製劑。 本發明之水性製劑之有效成分之唾喏酮化合物無無特限 ,可爲如下式(1)構造者。 200900066。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 。 [Prior Art] When an aqueous preparation is selected as a dosage form for a quinophthalone compound having an excellent antibacterial agent, insoluble microparticles in the form of a brown gel sometimes occur. The number of insoluble fine particles in the aqueous liquid preparation is not limited unless it is specified as the limit. Inhibition of the occurrence of insoluble fine particles, the addition of an organic acid, an amino acid, a polyaminocarboxylic acid or a polyvalent alcohol to the ozagrel sodium injection to suppress the formation of insoluble fine particles (Patent Documents 1 and 2). Further, a sugar alcohol is added to the quinacridone carboxylic acid-based antibacterial agent to suppress the decrease in the content during storage and the increase in the insoluble fine particles, thereby improving the stability (Patent Document 3). However, in these methods, there is a case where the effect of suppressing the formation of insoluble fine particles is insufficient. In the case of an aqueous preparation containing an alcohol, difloxacin is used as an active ingredient in an injection; L-arginine, propylene glycol, ethanol and benzyl alcohol are added to reduce the tissue damage at the site of administration (Patent Document 4) ). However, the effect of stabilization of aqueous preparations such as the effect of suppressing the formation of insoluble microparticles is still unknown. [Patent Document 1] JP-A-2003-63963 (PATENT DOCUMENT 2) JP-A-2006-63963 [PATENT DOCUMENT 3] US Patent No. 6,872,723 Contents 200900066 (Problem to be Solved by the Invention) The object of the present invention is to obtain a more stable aqueous preparation containing quinacridone. (Means for Solving the Problem) The inventors of the present invention have made efforts to review the suppression of insoluble fine particles by various additives. As a result, it was found that the addition of alcohols such as concentrated glycerin, absolute ethanol, and propylene glycol reduced the number of insoluble fine particles. Further, it has been found that the addition of the alcohol not only reduces the insoluble fine particles but also suppresses the formation of the terpenoids, and finally completed the present invention. C', i.e., the present invention is an aqueous preparation relating to the stability of a quinophthalone compound and an alcohol. Further, the present invention relates to a method for stabilizing an aqueous preparation containing quinacridone characterized by adding an alcohol to an aqueous solution containing a quinophthalone compound. (Effect of the Invention) The aqueous alcohol-added preparation of the present invention inhibits the occurrence of insoluble fine particles by the addition of an alcohol, and improves storage stability. Further, the addition of an alcohol can also inhibit the formation of an anthraquinone-like substance, and an aqueous preparation containing quinacridone which is stable in stability and stability can be improved. [Embodiment] (Best Mode for Carrying Out the Invention) The present invention relates to an aqueous preparation of an alcohol containing a quinophthalone compound as an active ingredient and a stabilizer component. The stilbene compound of the active ingredient of the aqueous preparation of the present invention is not limited, and may be a structure of the following formula (1). 200900066

[式中R1爲 碳數1~6之烷基、 碳數2〜6之烯基、 碳數1~6之齒烷基、 可有鹵原子取代之碳數3~6之環狀烷基、 碳數1~6之院氧基、 碳數1〜6之烷胺基、 .院基、或碳 ^可包括母核 硫原子爲環 代基。 1〜6之烷基 乏數1〜6之烷 i數之烷 可有鹵原子、羥基 '胺基、硝基、碳數1〜6 2 數1〜6之烷氧基取代之芳基、或 可有鹵原子或碳數1〜6之烷基取代之雜芳基; R2爲氫原子或碳數1~6之烷硫基;此R1與R 之一部分而一體化形成環狀構造,此環可含窄 之構成原子,此環更可有碳數1~6之烷基爲取 R3爲氫原子、胺基(此胺基可有甲醯基、碳數 或碳數2〜5之醯基取代)、硫醇基、鹵甲基、β 基、碳數2~6之烯基、碳數2~6之炔基、或® 氧基; Α1爲氮原子或如下式(2)部分構造、[wherein R1 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a chiral alkyl group having 1 to 6 carbon atoms, a cyclic alkyl group having 3 to 6 carbon atoms which may be substituted by a halogen atom, The alkoxy group having 1 to 6 carbon atoms, the alkylamino group having 1 to 6 carbon atoms, the phenyl group, or the carbon may include a nucleus atom as a nucleus. The alkane of the alkyl group having 1 to 6 alkyl groups may have a halogen atom, a hydroxyl group 'amine group, a nitro group, an alkoxy group substituted with a carbon number of 1 to 6 2 and 1 to 6 or an alkoxy group substituted with an alkoxy group, or a heteroaryl group which may have a halogen atom or an alkyl group having 1 to 6 carbon atoms; R2 is a hydrogen atom or an alkylthio group having 1 to 6 carbon atoms; and R1 and a part of R are integrated to form a cyclic structure, and the ring is formed. It may have a narrow constituent atom, and the ring may have an alkyl group having 1 to 6 carbon atoms, and R3 is a hydrogen atom or an amine group (the amine group may have a methyl group, a carbon number or a carbon number of 2 to 5). Substituted), thiol group, halomethyl group, β group, alkenyl group having 2 to 6 carbon atoms, alkynyl group having 2 to 6 carbon atoms, or oxy group; Α1 is a nitrogen atom or a partial structure of the following formula (2),

(2) (式中X2爲氫原子、胺基(此胺基可有甲醯基、碳數1〜6之 200900066 烷基或碳數2~5之醯基取代)、鹵原子、氰基、鹵甲基、鹵 甲氧基、碳數1〜6之烷基、碳數2~6之烯基、碳數2~6之 炔基、或碳數1〜6之烷氧基;此X2與上述R1可包括母核 之一部分而一體化形成環狀構造,如此形成之環此環可含 有氧原子、氮原子、或硫原子爲環之構成原子,此環更可 有碳數1~6之烷基爲取代基); A2及A3各相異爲氮原子或碳原子,但a1、A2及A3與這些 結合之碳原子形成如下部分構造(2) (wherein X2 is a hydrogen atom or an amine group (the amine group may have a methyl group, a carbon number of 1 to 6 of 200900066 alkyl or a carbon number of 2 to 5 thiol), a halogen atom, a cyano group, a halomethyl group, a halomethoxy group, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms; The above R1 may include a part of the mother nucleus and integrally form a ring structure, and the ring thus formed may contain an oxygen atom, a nitrogen atom, or a sulfur atom as a constituent atom of the ring, and the ring may have a carbon number of 1 to 6. The alkyl group is a substituent); each of A2 and A3 is a nitrogen atom or a carbon atom, but a1, A2 and A3 form a partial structure with these bonded carbon atoms as follows.

或如下部分構造 X1爲鹵原子或氫原子; Y爲氫原子、苯基、乙醯氧甲基、特戊醯氧甲基' 乙氧羰 基、甲基吡啶基、二甲胺基乙基、5 -氫茚基、酞基、5 -烷 基-2-氧-1,3-二噚茂-4-基甲基、3-乙醯氧基-2-氧丁基、碳 數1~6之烷基、碳數2〜7之烷氧甲基 '或由碳數1〜6之伸 烷基與苯基而構成之苯烷基; Z爲單環式、二環式、或三環式之雜環式取代基,此雜環 式取代基可飽和或部分飽和’可含有由氮原子、氧原子及 硫原子選擇之1以上之雜原子’更可爲雙環構造或螺環狀 構造,而可有由國原子、羥基、胺基、胺甲醯基、碳數 200900066 1〜6之烷基、碳數1〜6之鹵烷基、芳基、雜芳基、碳數 1〜6之烷氧基、碳數1~6之烷胺基、碳數1〜6之烷硫基、 及碳數1~6之胺烷基而成之群選擇之1或2以上之原子或 基取代]。 上述式(1)之化合物中,R1爲碳數1〜6之烷基;碳數2〜6 之烯基;碳數1~6之鹵烷基;可有鹵原子取代之碳數3〜6 之環狀烷基;碳數1~6之烷氧基;碳數1〜6之烷胺基;可 有鹵原子、羥基、胺基、硝基、碳數1~6之烷基、或碳數 1〜6之烷氧基取代之芳基;或可有鹵原子或碳數1〜6之烷 基取代之雜芳基。 碳數1〜6之烷基以乙基特佳。碳數2〜6之烯基以乙烯基 、或1-異丙烯基特佳。碳數之鹵烷基可爲具有氟原子 、氯原子、溴原子、碘原子等鹵原子之碳數1〜6之烷基, 以2-氟乙基特佳。碳數3~6之環狀烷基以環丙基特佳。環 狀烷基有取代基時,取代基以鹵原子較佳,以氟原子特佳 f 。此氟環丙基以2-(S)-氟-1-(R)-環丙基特佳。 芳基可爲有由例如氟原子、氯原子、溴原子等鹵原子、 羥基、胺基、硝基、碳數1~6之烷基、碳數1~6之烷氧基 而成之群選擇之1〜3個原子或基爲取代基之苯基,以苯基 、2-氟苯基、4 -氟苯基、2,4 -二氟苯基、2 -氟-4-羥苯基、3-胺基-4,6 -二氟苯基及4,6 -二氟-3-甲胺基苯基較佳。 雜芳基爲由可有以鹵原子或碳數1~6之烷基爲取代基之5 員環或6員環之芳香族雜環化合物誘導之芳香族雜環取代 基。雜芳基爲含有由氮原子、氧原子、硫原子選擇之1以 200900066 上雜原子,例如吡啶基、嘧啶基等,以6-胺基-3,5-二氟-2-吡陡基特佳。 碳數1〜6之院氧基以甲氧基特佳。碳數1〜6之院胺基以 甲胺基特佳。 取代基R1以環狀烷基或齒環烷基較佳。環狀烷基以環丙 基特佳,鹵環丙基以2 -鹵環丙基較佳,以2 -氟環丙基特佳 〇 式(1)中,R2爲氫原子或碳數1~6之烷硫基。碳數1〜6之 ( ' 烷硫基以甲硫基、乙硫基特佳。 取代基R2以氫原子較佳。 式(1)中,R1與R2可包括母核之一部分而一體化形成環狀 構造。此環可含有硫原子爲環之構成原子,此環更可有碳 數1~6之烷基爲取代基。此烷基以甲基較佳。 • 式U)中’ R3爲氫原子、胺基(此胺基可有甲醯基、碳數 1〜6之烷基或碳數2〜5之醯基(烷羰基)取代)、硫醇基 '鹵 甲基、碳數1〜6之烷基、碳數2~6之烯基、碳數2~6之炔 f :j 」 基、或碳數1~6之烷氧基。 可有甲醯基、碳數1〜6之烷基或碳數2〜5之醯基取代之 胺基可爲例如甲醯胺基、乙醯胺基等,以乙醯胺基特佳。 碳數1~6之烷基可爲甲基、乙基,以甲基特佳。碳數2-6 之烯基以乙烯基特佳。碳數2~6之炔基以乙炔基特佳。又 碳數1〜6之烷氧基以甲氧基特佳。 取代基R3以氫原子較佳。 式(1)中,A1爲氮原子或如式(2)部分構造 -10- 200900066 T⑵ ο 式(2)中,X2爲氫原子、胺基(此胺基可有甲醯基、碳數 1~6之院基或碳數2~5之酿基取代)、鹵原子、氰基 '鹵甲 基、鹵甲氧基、碳數1〜6之烷基、碳數2〜6之烯基、碳數 2~6之炔基、或碳數1〜6之烷氧基。 可有甲醯基、碳數1〜6之烷基或碳數2〜5之醯基取代之 胺基以乙醯胺基特佳。碳數1〜6之烷基以甲基特佳。碳數 2〜6之烯基以乙烯基特佳。碳數2〜6之炔基以乙炔基特佳 。又碳數1〜6之烷氧基以甲氧基特佳。 此X2與上述R1可包括母核之一部分而一體化形成環狀構 造,如此形成之環可含有氧原子、氮原子、或硫原子爲環 之構成原子。此環更可有碳數1〜6之烷基爲取代基。 如此形成之環構造宜爲ofloxacin等骨架之吡啶并苯并噚 畊骨架。此骨架之烷基取代基更以甲基較佳,特以(3 S)-甲 基較佳。 取代基A1以式(2)部分構造較佳’取代基X2以甲基、甲 氧基、二氟甲氧基較佳。 式(1)中,A2及A3各相異爲氮原子或碳原子。A1、A2及 A3與這些結合之碳原子形成爲如下部分構造Or X1 is a halogen atom or a hydrogen atom; Y is a hydrogen atom, a phenyl group, an acetoxymethyl group, a p-pentyloxymethyl 'ethoxycarbonyl group, a methylpyridyl group, a dimethylaminoethyl group, 5 -hydroindolyl, fluorenyl, 5-alkyl-2-oxo-1,3-dioxan-4-ylmethyl, 3-ethyloxy-2-oxobutyl, carbon number 1~6 An alkyl group, an alkoxymethyl group having 2 to 7 carbon atoms or a phenylalkyl group having a C 1 to 6 alkyl group and a phenyl group; Z is a monocyclic, bicyclic or tricyclic ring. a heterocyclic substituent which may be saturated or partially saturated 'may contain a hetero atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and may be a bicyclic structure or a spiro ring structure, but may be There are an atomic atom, a hydroxyl group, an amine group, an amine carbenyl group, an alkyl group having a carbon number of 200900066 1 to 6, a haloalkyl group having a carbon number of 1 to 6, an aryl group, a heteroaryl group, and an alkoxy group having a carbon number of 1 to 6. One or two or more atoms or groups of the group selected from the group consisting of an alkylamine having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, and an amine alkyl group having 1 to 6 carbon atoms are selected]. In the compound of the above formula (1), R1 is an alkyl group having 1 to 6 carbon atoms; an alkenyl group having 2 to 6 carbon atoms; a haloalkyl group having 1 to 6 carbon atoms; and a carbon number of 3 to 6 which may be substituted by a halogen atom. a cyclic alkyl group; an alkoxy group having 1 to 6 carbon atoms; an alkylamino group having 1 to 6 carbon atoms; may have a halogen atom, a hydroxyl group, an amine group, a nitro group, an alkyl group having 1 to 6 carbon atoms, or carbon An alkoxy-substituted aryl group of 1 to 6; or a heteroaryl group which may have a halogen atom or an alkyl group having 1 to 6 carbon atoms. The alkyl group having 1 to 6 carbon atoms is particularly preferably ethyl. The alkenyl group having 2 to 6 carbon atoms is particularly preferably a vinyl group or a 1-isopropenyl group. The haloalkyl group having a carbon number may be an alkyl group having 1 to 6 carbon atoms which has a halogen atom such as a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and is preferably a 2-fluoroethyl group. A cyclic alkyl group having 3 to 6 carbon atoms is particularly preferred as a cyclopropyl group. When the cyclic alkyl group has a substituent, the substituent is preferably a halogen atom, and the fluorine atom is particularly preferably f. This fluorocyclopropyl group is particularly preferably 2-(S)-fluoro-1-(R)-cyclopropyl. The aryl group may be selected from the group consisting of a halogen atom such as a fluorine atom, a chlorine atom or a bromine atom, a hydroxyl group, an amine group, a nitro group, an alkyl group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms. a phenyl group having 1 to 3 atoms or a substituent, and a phenyl group, a 2-fluorophenyl group, a 4-fluorophenyl group, a 2,4-difluorophenyl group, a 2-fluoro-4-hydroxyphenyl group, 3-Amino-4,6-difluorophenyl and 4,6-difluoro-3-methylaminophenyl are preferred. The heteroaryl group is an aromatic heterocyclic substituent which is induced by an aromatic heterocyclic compound which may have a 5-membered ring or a 6-membered ring which is a halogen atom or an alkyl group having 1 to 6 carbon atoms. The heteroaryl group is a hetero atom having a nitrogen atom, an oxygen atom or a sulfur atom selected from 200900066, such as a pyridyl group, a pyrimidinyl group or the like, and a 6-amino-3,5-difluoro-2-pyridyl group. good. The oxy group having a carbon number of 1 to 6 is particularly preferred as a methoxy group. The amine group having a carbon number of 1 to 6 is preferably a methylamino group. The substituent R1 is preferably a cyclic alkyl group or a ring-shaped cycloalkyl group. The cyclic alkyl group is preferably a cyclopropyl group, the halocyclopropyl group is preferably a 2-halocyclopropyl group, and the 2-fluorocyclopropyl group is preferably a formula (1), and R 2 is a hydrogen atom or a carbon number of 1~ 6 alkylthio. The carbon number is 1 to 6 ('the alkylthio group is preferably a methylthio group or an ethylthio group. The substituent R2 is preferably a hydrogen atom. In the formula (1), R1 and R2 may include a part of the mother nucleus and are integrally formed. The ring structure may contain a sulfur atom as a constituent atom of the ring, and the ring may have a carbon number of 1 to 6 as a substituent. The alkyl group is preferably a methyl group. • In the formula U), 'R3 is a hydrogen atom or an amine group (the amine group may have a methyl group, an alkyl group having 1 to 6 carbon atoms or a mercapto group having 2 to 5 carbon atoms (alkylcarbonyl group)), a thiol group halomethyl group, and a carbon number of 1 An alkyl group of ~6, an alkenyl group having 2 to 6 carbon atoms, an alkyne having a carbon number of 2 to 6 f:j" group, or an alkoxy group having 1 to 6 carbon atoms. The amine group which may have a mercapto group, an alkyl group having 1 to 6 carbon atoms or a mercapto group having 2 to 5 carbon atoms may be, for example, a formamidine group, an ethenyl group or the like, and is particularly preferably an acetamino group. The alkyl group having 1 to 6 carbon atoms may be a methyl group or an ethyl group, and is preferably a methyl group. The alkenyl group having 2 to 6 carbon atoms is particularly excellent in vinyl. The alkynyl group having 2 to 6 carbon atoms is particularly preferred as an ethynyl group. Further, the alkoxy group having 1 to 6 carbon atoms is particularly preferred as the methoxy group. The substituent R3 is preferably a hydrogen atom. In the formula (1), A1 is a nitrogen atom or a moiety as defined in the formula (2)-10-200900066 T(2) ο In the formula (2), X2 is a hydrogen atom or an amine group (this amine group may have a methyl group, a carbon number of 1) a group of ~6 or a carbon number of 2 to 5 substituted), a halogen atom, a cyano 'halomethyl group, a halomethoxy group, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, An alkynyl group having 2 to 6 carbon atoms or an alkoxy group having 1 to 6 carbon atoms. The amine group which may have a mercapto group, an alkyl group having 1 to 6 carbon atoms or a mercapto group having 2 to 5 carbon atoms is particularly preferably an acetamino group. The alkyl group having 1 to 6 carbon atoms is particularly preferred as a methyl group. The alkenyl group having 2 to 6 carbon atoms is particularly excellent in vinyl. The alkynyl group having a carbon number of 2 to 6 is particularly preferably an ethynyl group. Further, the alkoxy group having 1 to 6 carbon atoms is particularly preferred as the methoxy group. The X2 and the above R1 may include a part of the mother nucleus and be integrated to form a cyclic structure, and the ring thus formed may contain an oxygen atom, a nitrogen atom, or a constituent atom in which a sulfur atom is a ring. The ring may further have an alkyl group having 1 to 6 carbon atoms as a substituent. The ring structure thus formed is preferably a pyridobenzoindole skeleton of a framework such as ofloxacin. The alkyl substituent of this skeleton is more preferably a methyl group, and particularly preferably a (3S)-methyl group. The substituent A1 is preferably a moiety of the formula (2). The substituent X2 is preferably a methyl group, a methoxy group or a difluoromethoxy group. In the formula (1), each of A2 and A3 is a nitrogen atom or a carbon atom. A1, A2 and A3 form a partial structure with these bonded carbon atoms as follows

或如下部分構造 -11 - 200900066Or the following part of the structure -11 - 200900066

也即具有如下構造者 R3 QThat is, the following constructor R3 Q

C00YC00Y

N1RN1R

RR

這些部分構造中以如下部分構造較佳These partial configurations are preferably constructed in the following parts.

更A1以如前述式(2)之構造較佳’故以如下構造者較佳Further, A1 is preferably constructed as in the above formula (2), so that it is preferably constructed as follows.

C00Y .3C00Y .3

式(1)中,X1爲鹵原子或氫原子,若爲鹵原子時,以氟原 -12- 200900066 子較佳。 取代基X1以氟原子或氫原子較佳。 式(π中,γ爲氫原子、苯基、乙醯氧甲基、特 基、乙氧羰基、甲基吡啶基、二甲胺基乙基、5-献基、5-烷基-2-氧·ι,3-二噚茂-4-基甲基、3-乙@ 氧丁基、碳數1~6之烷基、碳數2〜7之烷氧甲基 數1~6之伸烷基與苯基構成之苯烷基。 取代基Υ以氮原子較佳。 、 k 又式(1)中,z爲單環式、二環式、或三環式之 代基。此雜環式取代基爲飽和或部分飽和,可含 子、氧原子及硫原子選擇之1以上之雜原子。更 構造或螺環狀構造。此雜環式取代基可有取代基 原子、羥基、胺基、胺甲醯基、碳數1~6之烷 ' 1~6之鹵烷基、芳基、雜芳基、碳數1〜6之烷氧 1〜6之烷胺基、碳數1~6之烷硫基或碳數1~6之 代。可於雜環式取代基取代之原子或基可爲1個 ^ 以上。 可於上述雜環式取代基取代之碳數1~6之烷基 鹵原子、羥基、胺基、胺甲醯基、碳數1〜6之鹵 數1〜6之烷氧基、碳數1~6之烷胺基、碳數1〜6 及碳數1〜6之胺烷基而成之群選擇之1以上之原 取代基,可於雜環式取代基取代之烷基’可於該 之鹵烷基、烷胺基、烷硫基及胺烷基之烷基部分 構造,更可有由鹵原子、碳數1~6之院基及碳數 戊醯氧甲 氫茚基、 €氧基-2-、或由碳 雜環式取 有由氮原 可爲雙環 ,例如鹵 基、碳數 基、碳數 胺烷基取 也可2個 可有以由 烷基、碳 之烷硫基 子或基爲 烷基取代 可有環狀 1〜6之烷 -13- 200900066 氧基而成之群選擇之1以上之原子或基爲取代基。 又上述胺基、烷胺基及胺烷基之胺基部分可有碳數 之烷基(此烷基可有環狀構造,也可有由羥基、鹵原子、碳 數1〜6之烷硫基及碳數1~6之烷氧基而成之群選擇之1以 上之原子或基爲取代基)1個或2個爲取代基,若2個時, 可相同或不同。更此胺基部分可以通常使用之保護基保護 〇 可有上述雜環式取代基取代之碳數1~6之鹵烷基、碳數 f \ I 1〜6之烷胺基、碳數1 ~6之烷硫基及碳數1 ~6之胺烷基之 烷基部分可有環狀構造,更可有由鹵原子、碳數1〜6之烷 基、碳數1~6之烷氧基、芳基及雜芳基而成之群選擇之1 以上之原子或基爲取代基。 可有上述雜環式取代基取代之胺基、碳數1〜6之烷胺基 及碳數1〜6之胺烷基之胺基部分可更有碳數1~6之烷基1 個或2個爲取代基、或可以保護基保護。胺基上之烷基爲 . 2個之場合,可相同或不同。 於此,碳數1~6之烷基可有環狀構造,也可有由鹵原子 、羥基、碳數1~6之烷硫基及碳數1〜6之烷氧基而成之群 選擇之1以上之原子或基爲取代基。 胺基之保護基只要爲此領域泛用者則無特限,例如第三 丁氧羰基、2,2,2-三氯乙氧羰基等烷氧羰基類;苄氧羰基 、對甲氧基苄氧羰基、對硝苄氧羰基等芳烷氧羰基類;乙 醯基、甲氧基乙醯基、三氟乙醯基、氯乙醯基、特戊醯基 、甲醯基、苄醯基等醯基類;第三丁基、苄基、對硝苄基 -14- 200900066 、對甲氧基苄基、三苯甲基等烷基類、或芳烷基類;甲氧 甲基、第三丁氧甲基、四氫吡喃基、2,2,2 -三氯乙氧甲基 等醚類;三甲基矽烷基、異丙基二甲基矽烷基、第三丁基 二甲基矽烷基、三苄基矽烷基、第三丁基二苯基矽烷基等( 烷基及/或芳烷基)取代矽烷基。 可於上述雜環式取代基取代之芳基爲碳數6~10,又雜芳 基爲5員環或6員環而可有1〜4個由氮原子、氧原子及硫 原子選擇之雜原子。 (' 可於上述雜環式取代基取代之芳基及雜芳基爲可有由鹵 原子、羥基、硫醇基、胺基、硝基、氰基、羧基、胺甲醯 基、苯基、碳數1~6之烷基、碳數1〜6之烷氧基、碳數 1~6之烷硫基、碳數2~6之烷氧羰基、碳數2~5之醯基及 雜芳基(5員環或6員環,而含1〜4個由氮原子、氧原子及 ' 硫原子選擇之雜原子)而成之群選擇之1以上之原子或基爲 取代基。 於此,可於芳基及雜芳基取代之苯基、碳數1~6之烷基 k 、碳數1~6之烷氧基、碳數1〜6之烷硫基 '碳數2~6之烷 氧羰基、碳數2~5之醯基及雜芳基爲更可有由鹵原子、經 基、碳數1~6之烷氧基、碳數1〜6之烷硫基而成之群選擇 之1以上之原子或基爲取代基。又可於芳基及雜芳基取代 之胺基爲更可有由甲醯基、碳數丨~6之烷基、碳數2~5之 酸基及碳數2〜5之院氧裁基而成之群選擇之1或2之基爲 取代基。 取代基Z可仲介構成環之任何原子而與喹喏酮母格結合 -15- 200900066 ,唯以於氮原子結合較佳。如此以氮原子結合之雜環式取 代基爲如下式(3)〜(7)構造之取代基: 式⑶In the formula (1), X1 is a halogen atom or a hydrogen atom, and when it is a halogen atom, it is preferably a fluorogenic -12-200900066. The substituent X1 is preferably a fluorine atom or a hydrogen atom. In the formula (π, γ is a hydrogen atom, phenyl, acetoxymethyl, thiol, ethoxycarbonyl, methylpyridyl, dimethylaminoethyl, 5-entributyl, 5-alkyl-2- Oxygen, iota, 3-dimethyl-4-ylmethyl, 3-ethyl@oxybutyl, alkyl having 1 to 6 carbon atoms, alkyloxymethyl group having 1 to 6 carbon atoms and 1 to 6 alkylene The phenyl group consisting of a phenyl group and a phenyl group. The substituent Υ is preferably a nitrogen atom. k is a compound of the formula (1), and z is a monocyclic, bicyclic or tricyclic substituent. The substituent is saturated or partially saturated, and may have a hetero atom of one or more selected from the group consisting of a donor, an oxygen atom and a sulfur atom. A more structural or spirocyclic structure. The heterocyclic substituent may have a substituent atom, a hydroxyl group, an amine group, Aminomethyl fluorenyl group, a C 1~6 alkane '1~6 haloalkyl group, an aryl group, a heteroaryl group, an alkyl alkoxy group having 1 to 6 carbon atoms of 1 to 6 and a carbon number of 1 to 6 An alkylthio group or a carbon number of 1 to 6. The atom or group which may be substituted with a heterocyclic substituent may be 1 or more. The alkyl halide having 1 to 6 carbon atoms which may be substituted with the above heterocyclic substituent Atom, a hydroxyl group, an amine group, an amine carbenyl group, an alkoxy group having a carbon number of 1 to 6 and a halogen number of 1 to 6, and an alkylamine having 1 to 6 carbon atoms An alkyl group having 1 to 6 carbon atoms and 1 to 6 carbon atoms selected from the group consisting of an original substituent of 1 or more, and an alkyl group which may be substituted with a heterocyclic substituent may be a haloalkyl group or an alkane The alkyl moiety of the amine group, the alkylthio group and the amine alkyl group may further have a halogen atom, a carbon number of 1 to 6 and a carbon number pentamyl methoxymethyl hydrazine group, an oxy group, or The carbon heterocyclic ring may be a bicyclic ring derived from a nitrogen atom, for example, a halogen group, a carbon number group, or a carbon number amino group, or two may be substituted by an alkyl group, a carbon alkyl group or a group. One or more atoms or groups selected from the group consisting of a cyclic 1 to 6 alkane-13-200900066 oxy group may be a substituent. Further, the amine group of the above amine group, alkylamino group and amine alkyl group may have carbon. a number of alkyl groups (the alkyl group may have a cyclic structure, or may be selected from the group consisting of a hydroxyl group, a halogen atom, an alkylthio group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms; One or two of the substituents are one or two substituents, and if they are two, they may be the same or different. Further, the amine moiety may be protected by a protecting group which is usually used, and may be substituted with the above heterocyclic substituent. The alkyl group having 1 to 6 haloalkyl groups, the carbon number f \ I 1 to 6 alkyl group, the alkyl group having 1 to 6 carbon atoms, and the alkyl group having 1 to 6 carbon atoms may have a cyclic structure. Further, an atom or a group selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an aryl group and a heteroaryl group may be a substituent. The amine group having an amino group substituted with the above heterocyclic substituent, an alkylamino group having 1 to 6 carbon atoms, and an amine alkyl group having 1 to 6 carbon atoms may have 1 or more alkyl groups having 1 to 6 carbon atoms. The substituents may be protected by a protecting group. The alkyl group on the amine group may be the same or different in the case of two alkyl groups. Here, the alkyl group having 1 to 6 carbon atoms may have a cyclic structure or may be One or more atoms or groups selected from the group consisting of a halogen atom, a hydroxyl group, an alkylthio group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms are substituents. The protecting group of the amine group is not limited as long as it is widely used in the field, for example, an alkoxycarbonyl group such as a third butoxycarbonyl group or a 2,2,2-trichloroethoxycarbonyl group; a benzyloxycarbonyl group and a p-methoxybenzyl group; An aralkoxycarbonyl group such as an oxycarbonyl group or a p-benzyloxycarbonyl group; an ethyl fluorenyl group, a methoxyethyl fluorenyl group, a trifluoroethyl fluorenyl group, a chloroethylene group, a pentamidine group, a decyl group, a benzhydryl group, or the like. Terpenyl; butyl, benzyl, p-nitrobenzyl-14- 200900066, p-methoxybenzyl, trityl, etc. alkyl, or aralkyl; methoxymethyl, third Ethers such as butoxymethyl, tetrahydropyranyl, 2,2,2-trichloroethoxymethyl; trimethyldecyl, isopropyldimethylhydrazine, tert-butyldimethylsilane The alkyl group, the tribenzyl decyl group, the tert-butyl diphenyl fluorenyl group, etc. (alkyl and/or aralkyl) are substituted for the decyl group. The aryl group which may be substituted with the above heterocyclic substituent is a carbon number of 6 to 10, and the heteroaryl group is a 5-membered ring or a 6-membered ring, and may have 1 to 4 kinds of impurities selected from a nitrogen atom, an oxygen atom and a sulfur atom. atom. (' The aryl and heteroaryl group which may be substituted with the above heterocyclic substituent may be a halogen atom, a hydroxyl group, a thiol group, an amine group, a nitro group, a cyano group, a carboxyl group, an amine carbaryl group, a phenyl group, Alkyl groups having 1 to 6 carbon atoms, alkoxy groups having 1 to 6 carbon atoms, alkylthio groups having 1 to 6 carbon atoms, alkoxycarbonyl groups having 2 to 6 carbon atoms, fluorenyl groups having 2 to 5 carbon atoms, and heteroaryl groups One or more atoms or groups selected from the group consisting of a 5-membered ring or a 6-membered ring and having 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a 'sulfur atom are substituted groups. a phenyl group substituted with an aryl group and a heteroaryl group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having a carbon number of 1 to 6 and a carbon number of 2 to 6 The oxycarbonyl group, the fluorenyl group having 2 to 5 carbon atoms and the heteroaryl group are selected from the group consisting of a halogen atom, a meridine group, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. One or more of the atoms or groups are a substituent. The amine group which may be substituted with an aryl group and a heteroaryl group may be an alkyl group having a methyl group, a carbon number of 丨6, or an acid group having a carbon number of 2 to 5. And the group of 1 or 2 selected from the group of carbon number 2 to 5 is a substituent. The substituent Z can be a ring to form a ring. Any atom is bonded to the quinacridone parent group -15-200900066, and the nitrogen atom is preferably bonded only. The heterocyclic substituent bonded to the nitrogen atom is a substituent of the following formula (3) to (7): Formula (3)

[式中R4、R5、R5’ 、R6、R6’ 、R7及R8爲如前述Z所示 雜環式取代基之取代基。更具體而言, R4、R5及R6各自獨立爲氫原子或碳數1〜6之烷基, 若此烷基爲可有由鹵原子、羥基、胺基、胺甲醯基 '碳 數卜6之烷硫基、碳數1〜6之烷氧基、碳數1〜6之烷胺基 、碳數1〜6之鹵烷基及碳數1〜6之胺烷基而成之群之基選 擇之1以上之基爲取代基、 上述烷基,可於該烷基取代之烷硫基、烷胺基、鹵烷基 及胺烷基之烷基部分可有環狀構造,更可有由鹵原子、碳 數1~6之烷基、烷氧基而成之群之選擇之1以上之原子或 基爲取代基。 又可於烷基取代之胺基、胺烷基及烷胺基之胺基部分可 有碳數1~6之烷基(此烷基可有環狀構造,又可有由鹵原子 、羥基、碳數1〜6之烷硫基及碳數1~6之烷氧基而成之群 選擇之1以上之原子或基爲取代基)1個或2個爲取代基( 若爲2個時,可相同或不同),更於此胺基部分可以通常使 用之保護基保護。 R5’及R6’各自獨立爲氫原子、芳基、或雜芳基,唯此 -16- 200900066 芳基爲碳數6〜10,又雜芳基爲5員環或6員環而可有1個 〜4個由氮原子、氧原子及硫原子任意選擇之雜原子, 上述芳基及雜芳基可有由鹵原子、羥基、硫醇基、胺基 、硝基、氰基、羧基、胺甲醯基、苯基、碳數1~6之烷基 、碳數1~6之烷氧基、碳數1~6之烷硫基、碳數2〜6之烷 氧羰基、碳數2~5之醯基及雜芳基(5員環或6員環而可有 1個〜4個由氮原子、氧原子及硫原子任意選擇之雜原子)而 成之群選擇之1以上之原子或基爲取代基, Γ' k 其中之烷基、烷氧基、烷硫基、烷氧羰基、醯基、苯基 及雜芳基可有由鹵原子、羥基、碳數1〜6之烷氧基及碳數 1〜6之烷硫基而成之群選擇之1以上之原子或基爲取代基 ,而胺基可有由甲醯基、碳數1〜6之烷基、碳數2〜5之醯 基及碳數2~5之烷氧羰基而成之群之基選擇之1或2之基 ' 爲取代基。 R7及R8各自獨立爲氫原子或碳數1~6之烷基。 由上述R5、R5’ 、R6及R6’選擇之任意2個爲可一體化 形成環狀構造而可有由氧原子、氮原子、及硫原子任意選 擇之1以上之雜原子爲其環之構成原子。 如此形成之環可有由鹵原子、羥基、胺基、碳數丨〜6之 烷基、碳數1~6之烷氧基及碳數1~6之烷硫基而成之群選 擇之1以上之原子或基爲取代基,此胺基更可有由甲醯基 、碳數1〜6之烷基、碳數2~5之醯基及碳數2〜5之烷氧羰 基而成之群之基選擇之1或2基爲取代基], 或如下式(4) -17- 200900066[wherein R4, R5, R5', R6, R6', R7 and R8 are a substituent of the heterocyclic substituent as shown in the above Z. More specifically, each of R4, R5 and R6 is independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and if the alkyl group is a halogen atom, a hydroxyl group, an amine group or an amine group, the carbon number is 6 a group of an alkylthio group, an alkoxy group having 1 to 6 carbon atoms, an alkylamino group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, and an amine alkyl group having 1 to 6 carbon atoms. The alkyl group selected as the substituent or the alkyl group may have a cyclic structure in the alkyl moiety of the alkyl-substituted alkylthio group, the alkylamino group, the haloalkyl group and the amine alkyl group, and more preferably One or more atoms or groups selected from the group consisting of a halogen atom, an alkyl group having 1 to 6 carbon atoms, and an alkoxy group are substituents. Further, the amino group substituted with an alkyl group, an amine alkyl group and an alkylamino group may have an alkyl group having 1 to 6 carbon atoms (the alkyl group may have a cyclic structure or may have a halogen atom, a hydroxyl group, or One or two or more substituents are selected from the group consisting of an alkylthio group having 1 to 6 carbon atoms and an alkoxy group having 1 to 6 carbon atoms, and a substituent (if two, The same or different), and more preferably the amine moiety can be protected by a protecting group which is usually used. R5' and R6' are each independently a hydrogen atom, an aryl group or a heteroaryl group, and the -16-200900066 aryl group has a carbon number of 6 to 10, and the heteroaryl group is a 5-membered ring or a 6-membered ring. ~4 hetero atoms selected arbitrarily from a nitrogen atom, an oxygen atom and a sulfur atom, the above aryl and heteroaryl groups may have a halogen atom, a hydroxyl group, a thiol group, an amine group, a nitro group, a cyano group, a carboxyl group, an amine group Mercapto group, phenyl group, alkyl group having 1 to 6 carbon atoms, alkoxy group having 1 to 6 carbon atoms, alkylthio group having 1 to 6 carbon atoms, alkoxycarbonyl group having 2 to 6 carbon atoms, carbon number 2~ a group of 5 or more selected from the group consisting of a sulfhydryl group and a heteroaryl group (a 5-membered ring or a 6-membered ring may have one to four hetero atoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom) The substituent is a substituent, Γ' k wherein the alkyl group, the alkoxy group, the alkylthio group, the alkoxycarbonyl group, the fluorenyl group, the phenyl group and the heteroaryl group may have an alkoxy group having a halogen atom, a hydroxyl group and a carbon number of 1 to 6. One or more atoms or groups selected from the group consisting of an alkylthio group having 1 to 6 carbon atoms are a substituent, and the amine group may have a methyl group, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 2 to 2. Base selection of a group of 5 thiol groups and alkoxycarbonyl groups having 2 to 5 carbon atoms The base of 1 or 2 is chosen as a substituent. R7 and R8 are each independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms. Any two selected from the above R5, R5', R6, and R6' may form a cyclic structure integrally, and may have a hetero atom of one or more selected from an oxygen atom, a nitrogen atom, and a sulfur atom. atom. The ring thus formed may have a group selected from the group consisting of a halogen atom, a hydroxyl group, an amine group, an alkyl group having a carbon number of 丨6, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. The above atom or group is a substituent, and the amine group may further comprise a mercapto group, an alkyl group having 1 to 6 carbon atoms, a fluorenyl group having 2 to 5 carbon atoms, and an alkoxycarbonyl group having 2 to 5 carbon atoms. The group 1 or 2 of the group is selected as a substituent], or the following formula (4) -17- 200900066

[式中 R7、R7’ 、R8、R8’ ' R9 ' R10 ' R10> 、R11 及 R11’ 爲前述Z所示雜環式取代基上之取代基。更具體而言, R11及R11’各自獨立爲氫原子或碳數卜6之烷基, 此烷基可有由鹵原子、羥基、胺基、胺甲醯基、碳數1〜6 之烷硫基、碳數1~6之烷氧基、碳數1〜6之烷胺基、碳數 1〜6之鹵烷基及碳數1~6之胺烷基而成之群選擇之1以上 之原子或基爲取代基, R9、R1()及R1()’各自獨立爲氫原子、鹵原子、胺基、羥 基、胺甲醯基、碳數1~6之烷基、碳數1〜6之烷胺基、芳 基、雜芳基、碳數1~6之烷氧基、碳數1~6之烷硫基、碳 數1〜6之鹵烷基、或碳數1〜6之胺烷基, 此烷基、烷硫基、鹵烷基、胺烷基及烷胺基之烷基部分 可有環狀構造, 更可有由鹵原子、碳數1~6之烷基、碳數1~6之烷氧基 而成之群選擇之1以上之原子或基爲取代基, 又上述胺基、烷胺基及胺烷基之胺基部分可有碳數 之烷基(此烷基可有環狀構造,又可有由鹵原子、羥基、碳 數1 ~6之烷硫基及碳數1〜6之烷氧基而成之群選擇之1以 上之原子或基爲取代基)1個或2個爲取代基(若爲2個時 可相同或不同),此胺基部分更可以通常使用之保護基保護 -18- 200900066 更上述芳基爲碳數6〜10,又雜芳基爲5員環或6員環、 可有1個〜4個由氮原子、氧原子及硫原子任意選擇之雜原 子, 上述芳基及雜芳基可有由鹵原子、羥基、硫醇基 '胺基 、硝基、氰基、羧基、胺甲醯基、苯基、碳數1~6之烷基 、碳數1~6之烷氧基、碳數1〜6之烷硫基、碳數2〜6之烷 氧羰基、碳數2〜5之醯基及雜芳基(5員環或6員環,而可 有1個~4個由氮原子、氧原子及硫原子任意選擇之雜原子 ^ )而成之群選擇之1以上之原子或基爲取代基, 其中之烷基、烷氧基、烷硫基、烷氧羰基、醯基 '苯基 及雜芳基可有由鹵原子、羥基、碳數1〜6之烷氧基及碳數 1~6之烷硫基而成之群選擇之1以上之原子或基爲取代基 ,而胺基可有由甲醯基、碳數丨~6之烷基、碳數2~5之醯 ' 基及碳數2~5之烷氧羰基而成之群之基選擇之1或2之基 爲取代基。 R7、R7’ 、R8及R8’各自獨立爲氫原子或碳數1〜6之烷 基。 由上述、R7、R7’ 、R8、R8’ 、R9、Rl()及 R1()’ 選擇之任 意2個可一體化形成環狀構造,而可有由氧原子、氮原子 、及硫原子任意選擇之1以上之雜原子爲其環之構成原子 〇 如此形成之環可有由鹵原子、羥基、胺基、碳數1〜6之 烷基、碳數1~6之烷氧基及碳數1~6之烷硫基而成之群選 擇之1以上之原子或基爲取代基’此胺基更可有由甲醯基 -19- 200900066 、碳數1~6之烷基、碳數2~5之醯基及碳數2〜5之烷氧幾 基而成之群之基選擇之1或2基爲取代基] 或如下式(5)[wherein R7, R7', R8, R8' 'R9 'R10 'R10>, R11 and R11' are the substituents on the heterocyclic substituent represented by the above Z. More specifically, each of R11 and R11' is independently a hydrogen atom or an alkyl group having a carbon number of 6, and the alkyl group may have an alkylthio group having a halogen atom, a hydroxyl group, an amine group, an amine formazan group, and a carbon number of 1 to 6. One or more groups selected from the group consisting of alkoxy groups having 1 to 6 carbon atoms, alkylamino groups having 1 to 6 carbon atoms, haloalkyl groups having 1 to 6 carbon atoms, and amine alkyl groups having 1 to 6 carbon atoms. The atom or the group is a substituent, and R9, R1() and R1()' are each independently a hydrogen atom, a halogen atom, an amine group, a hydroxyl group, an amine carbenyl group, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 1 to 6 An alkylamino group, an aryl group, a heteroaryl group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, or an amine having 1 to 6 carbon atoms. The alkyl group, the alkyl moiety of the alkyl group, the alkylthio group, the haloalkyl group, the amine alkyl group and the alkylamino group may have a cyclic structure, and may further have a halogen atom, an alkyl group having 1 to 6 carbon atoms, and a carbon number. One or more atoms or groups selected from the group consisting of 1 to 6 alkoxy groups are substituents, and the amino group of the above amine group, alkylamino group and amine alkyl group may have an alkyl group having a carbon number (this alkyl group) It may have a cyclic structure, and may have a halogen atom, a hydroxyl group, an alkylthio group having 1 to 6 carbon atoms, and a carbon number of 1 to 6 The group in which the oxy group is selected is one or more atoms or a substituent is a substituent. One or two are substituents (if two or more may be the same or different), the amine moiety may be protected by a commonly used protecting group. -18- 200900066 Further, the above aryl group is a carbon number of 6 to 10, and the heteroaryl group is a 5-membered ring or a 6-membered ring, and may have 1 to 4 hetero atoms selected arbitrarily by a nitrogen atom, an oxygen atom and a sulfur atom. The above aryl and heteroaryl groups may have a halogen atom, a hydroxyl group, a thiol 'amine group, a nitro group, a cyano group, a carboxyl group, an amine methyl group, a phenyl group, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 1. Alkoxy group of ~6, alkylthio group having 1 to 6 carbon atoms, alkoxycarbonyl group having 2 to 6 carbon atoms, mercapto group having 2 to 5 carbon atoms, and heteroaryl group (5-membered ring or 6-membered ring) One or more atoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom, optionally selected, are selected from the group consisting of more than one atom or a substituent, wherein the alkyl group, the alkoxy group, and the alkylthio group are selected. The alkoxycarbonyl group, the fluorenyl 'phenyl group and the heteroaryl group may be selected from the group consisting of a halogen atom, a hydroxyl group, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. An atom or a base is a substituent, and The amine group may have a base of 1 or 2 selected from the group consisting of a methyl group, a carbon number of 丨~6, a carbon number of 2 to 5, and an alkoxycarbonyl group having 2 to 5 carbon atoms. As a substituent. R7, R7', R8 and R8' are each independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms. Any two selected from the above, R7, R7', R8, R8', R9, Rl(), and R1()' may be integrated to form a cyclic structure, and may be optionally composed of an oxygen atom, a nitrogen atom, and a sulfur atom. The hetero atom selected as one or more is a constituent atom of the ring, and the ring thus formed may have a halogen atom, a hydroxyl group, an amine group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and a carbon number. The group of 1 to 6 alkylthio groups is selected to be more than 1 atom or the substituent is a substituent. The amine group may further have a methyl group 19-200900066, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 2 The base of the group of ~5 and the alkoxy group of 2 to 5 carbon atoms are selected as the substituent or the substituent is as follows] or the following formula (5)

[式中 R7、R7’ 、R8、R8’ ' R9 ' R10 ' R10' ' R" ' R11'、 R12及R12’爲前述Z所示雜環式取代基上之取代基。更具 體而言, R11及R11’各自獨立爲氫原子或碳數丨~6之院基,而此院 基可有由鹵原子、羥基、胺基、胺甲醯基、碳數1~6之烷 硫基及碳數丨~6之烷氧基、碳數1〜6之烷胺基、碳數1〜6 之鹵烷基及碳數丨〜6之胺烷基而成之群選擇之1以上之原 子或基爲取代基。 R9、R1()及Rl°’各自獨立爲氫原子、幽原子、羥基、胺基 、胺甲醯基、碳數之烷基、碳數1~6之烷胺基、芳基 、雜芳基、碳數1〜6之院氧基、碳數1~6之院硫基、碳數 1~6之鹵烷基、或碳數1〜6之胺烷基’ 上述烷基、烷硫基、鹵烷基、胺烷基及碳數烷胺基之烷 基部分可有環狀構造,更可有由鹵原子、碳數1~6之院基 、碳數1~6之烷氧基而成之群選擇之1以上之原子或基爲 取代基。 又上述胺基、烷胺基及胺烷基之胺基部分可有碳數1 之烷基(此烷基可有環狀構造,又可有由鹵原子、羥基、碳 -20- 200900066 數1〜6之烷硫基及碳數1〜6之烷氧基而成之群選擇之1以 上之原子或基爲取代基)1個或2個爲取代基(若2個時可 相同或不同),此胺基部分更可以通常使用之保護基保護。 R12及R12’各自獨立爲氫原子、碳數1~6之烷基、芳基 、或雜芳基。 此芳基爲碳數6~10,又雜芳基爲5員環或6員環、可有 1個〜4個由氮原子、氧原子及硫原子任意選擇之雜原子' 上述芳基及雜芳基可有由鹵原子、羥基、硫醇基、胺基 Ο 、硝基、氰基、羧基、胺甲醯基、苯基、碳數1〜6之烷基 、碳數卜6之院氧基、碳數1~6之院硫基、碳數2〜6之丈兀 氧羰基、碳數2~5之醯基及雜芳基(5員環或6員環’而可 有1個〜4個由氮原子、氧原子及硫原子任意選擇之雜原子 ' )而成之群選擇之1以上原子或基爲取代基, ' 其中之烷基、烷氧基、烷硫基、烷氧羰基、醯基、苯基 及雜芳基可有由鹵原子 '羥基、碳數1~6之烷氧基及碳數 1〜6之烷硫基而成之群選擇之1以上原子或基爲取代基, ^ 而胺基更可有由甲醯基、碳數1~6之烷基、碳數2〜5之醯 基及碳數2~5之烷氧羰基而成之群之基選擇之1或2基爲 取代基。 R7、R7’ 、R8及R8’各自獨立爲氫原子或碳數1〜6之烷 基。 由上述、H7、R7, 、R8、R8’ ' R9 ' R10 ' R10, 、R12 及 R12'選擇之任意2個可一體化形成環狀構造’而可有由氧 原子、氮原子、及硫原子任意選擇之1以上之雜原子爲其 -21 - 200900066 環之構成原子。 如此形成之環可有由鹵原子、羥基、胺基、碳數1〜6之 烷基、碳數1~6之烷氧基及碳數1~6之烷硫基而成之群選 擇之1以上原子或基爲取代基,此胺基更可有由甲醯基、 碳數1〜6之烷基、碳數2〜5之醯基及碳數2〜5之烷氧羰基 而成之群之基選擇之1或2基爲取代基] 或如下式(6)[wherein R7, R7', R8, R8' 'R9 ' R10 ' R10' ' R" 'R11', R12 and R12' are the substituents on the heterocyclic substituent represented by the above Z. More specifically, R11 and R11' are each independently a hydrogen atom or a carbon number of 丨~6, and the base may have a halogen atom, a hydroxyl group, an amine group, an amine mercapto group, and a carbon number of 1 to 6. A group selected from the group consisting of an alkylthio group and an alkoxy group having a carbon number of 丨6, an alkylamino group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, and an amine alkyl group having a carbon number of 丨6. The above atom or group is a substituent. R9, R1() and Rl°' are each independently a hydrogen atom, a quiescent atom, a hydroxyl group, an amine group, an amine carbenyl group, an alkyl group having a carbon number, an alkylamino group having 1 to 6 carbon atoms, an aryl group or a heteroaryl group. , an alkoxy group having a carbon number of 1 to 6, a thiol group having a carbon number of 1 to 6, a haloalkyl group having a carbon number of 1 to 6, or an alkyl group having a carbon number of 1 to 6 'the above alkyl group, an alkylthio group, The alkyl moiety of the haloalkyl group, the amine alkyl group and the carbon number alkylamino group may have a cyclic structure, and may further comprise a halogen atom, a hospital group having 1 to 6 carbon atoms, and an alkoxy group having 1 to 6 carbon atoms. One or more of the atoms or groups selected as the group are substituents. Further, the amine group of the above amino group, alkylamino group and amine alkyl group may have an alkyl group having 1 carbon number (the alkyl group may have a cyclic structure, or may have a halogen atom, a hydroxyl group, or a carbon-20-200900066 number 1 One or two or more substituents selected from the group consisting of an alkylthio group of 1-6 and an alkoxy group having 1 to 6 carbon atoms are one or two substituents (the same or different if two) This amine moiety can be protected by a protecting group which is usually used. R12 and R12' are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an aryl group or a heteroaryl group. The aryl group is a carbon number of 6 to 10, and the heteroaryl group is a 5-membered ring or a 6-membered ring, and may have one to four hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom. The aryl group may have a halogen atom, a hydroxyl group, a thiol group, an amine group, a nitro group, a cyano group, a carboxyl group, an amine group, a phenyl group, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 6 Base, carbon number 1~6 sulphur base, carbon number 2~6 兀 兀 oxycarbonyl, carbon number 2~5 sulfhydryl and heteroaryl (5 member ring or 6 member ring ' and may have 1 ~ Four or more atoms or groups selected from the group consisting of four nitrogen atoms, oxygen atoms and sulfur atoms arbitrarily selected as a substituent, 'alkyl group, alkoxy group, alkylthio group, alkoxycarbonyl group The mercapto group, the phenyl group and the heteroaryl group may be substituted by a group of 1 or more atoms selected from the group consisting of a halogen atom 'hydroxy group, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. Base, ^ and the amine group may have a group consisting of a fluorenyl group, an alkyl group having 1 to 6 carbon atoms, a fluorenyl group having 2 to 5 carbon atoms, and an alkoxycarbonyl group having 2 to 5 carbon atoms. Or 2 is a substituent. R7, R7', R8 and R8' are each independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms. Any two selected from the above, H7, R7, R8, R8' 'R9 'R10 'R10, R12 and R12' may be integrated to form a cyclic structure, and may have an oxygen atom, a nitrogen atom, and a sulfur atom. Any one or more of the heteroatoms selected is the constituent atom of the -21 - 200900066 ring. The ring thus formed may have a group selected from the group consisting of a halogen atom, a hydroxyl group, an amine group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. The above atom or group is a substituent, and the amine group may further comprise a group consisting of a fluorenyl group, an alkyl group having 1 to 6 carbon atoms, a fluorenyl group having 2 to 5 carbon atoms, and an alkoxycarbonyl group having 2 to 5 carbon atoms. The base of choice 1 or 2 is a substituent] or the following formula (6)

[式中 R"、R13, ' R'4 ' R14' 、R15、R16 及 R16,爲前述 Z 所示雜環式取代基上之取代基。更具體而言, R13及R13’各自獨立爲氫原子或碳數1~6之烷基, 此烷基可有由鹵原子、羥基、胺基、胺甲醯基、碳數1~6 之烷硫基及碳數1~6之烷氧基、碳數1~6之烷胺基、碳數 1~6之鹵烷基及碳數卜6之胺烷基而成之群選擇之1以上 之原子或基爲取代基。 R14、R14’ 、R15、R16及R16’各自獨立爲氫原子、鹵原子 、羥基、胺基、胺甲醯基、碳數1~6之烷基、碳數1〜6之 烷胺基、芳基、雜芳基、碳數1~6之烷氧基、碳數1〜6之 烷硫基、碳數1~6之鹵烷基、或碳數1〜6之胺烷基, 上述烷基、烷硫基、鹵烷基、胺烷基及烷胺基之烷基部 分可有環狀構造,更可有由鹵原子、碳數之烷基、碳 數1〜6之烷氧基而成之群選擇之1以上之原子或基爲取代 -22- 200900066 基。 又上述胺基、胺烷基及烷胺基之胺基部分可有碳數1〜6 之烷基(此烷基可有環狀構造,又可有由鹵原子、羥基、碳 數1〜6之烷硫基及碳數1~6之烷氧基而成之群選擇之1以 上之原子或基爲取代基)1個或2個爲取代基(若2個時可 相同或不同),此胺基部分更可以通常使用之保護基保護。 上述芳基爲碳數6~10,又雜芳基爲5員環或6員環,而 可有1個〜4個由氮原子、氧原子及硫原子任意選擇之雜原 ί :: 子, 上述芳基及雜芳基可有由鹵原子、羥基、硫醇基、胺基 、硝基、氰基、羧基、胺甲醯基、苯基、碳數1~6之烷基 、碳數1~6之烷氧基、碳數1~6之烷硫基、碳數2〜6之烷 氧羰基、碳數2~5之醯基及雜芳基(5員環或6員環,而可 ' 有1個〜4個由氮原子、氧原子及硫原子任意選擇之雜原子 )而成之群選擇之1以上原子或基爲取代基, 其中之烷基、烷氧基、烷硫基、烷氧羰基、醯基、苯基 > 及雜芳基可有由鹵原子、羥基、碳數1〜6之烷氧基及碳數 1~6之烷硫基而成之群選擇之1以上原子或基爲取代基, 而胺基更可有由甲醯基、碳數1~6之烷基、碳數2~5之醯 基及碳數2~5之烷氧羰基而成之群之基選擇之1或2基爲 取代基。 上述Rm、R14’ 、R15、R16&R16’選擇之任意2個可一 體化形成環狀構造,而可有由氧原子、氮原子、及硫原子 任意選擇之1以上雜原子爲其環之構成原子。 -23 - 200900066 如此形成之環可有由鹵原子、經基、胺基、碳數1~6之 烷基、碳數1〜6之烷氧基及碳數1〜6之烷硫基而成之群選 擇之1以上原子或基爲取代基,此胺基更可有由甲醯基、 碳數1~6之烷基、碳數2~5之醯基及碳數2〜5之烷氧羰基 而成之群之基選擇之1或2基爲取代基] 或如下式(7)[wherein R", R13, 'R'4' R14', R15, R16 and R16 are the substituents on the heterocyclic substituent represented by the above Z. More specifically, R13 and R13' are each independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and the alkyl group may have an alkyl group having a halogen atom, a hydroxyl group, an amine group, an amine carbenyl group, and a carbon number of 1 to 6. One or more selected from the group consisting of a sulfur group and an alkoxy group having 1 to 6 carbon atoms, an alkylamino group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, and an amine alkyl group having a carbon number of 6 An atom or a base is a substituent. R14, R14', R15, R16 and R16' are each independently a hydrogen atom, a halogen atom, a hydroxyl group, an amine group, an amine carbenyl group, an alkyl group having 1 to 6 carbon atoms, an alkylamino group having 1 to 6 carbon atoms, and an aromatic group. a base, a heteroaryl group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, or an alkyl group having 1 to 6 carbon atoms, and the above alkyl group The alkyl moiety of the alkylthio group, the haloalkyl group, the amine alkyl group and the alkylamino group may have a cyclic structure, and may further have a halogen atom, an alkyl group having a carbon number, and an alkoxy group having a carbon number of 1 to 6. The group or group of atoms or groups selected by the group is substituted for the -22-200900066 base. Further, the amine group of the above amine group, amine alkyl group and alkylamino group may have an alkyl group having 1 to 6 carbon atoms (the alkyl group may have a cyclic structure, or may have a halogen atom, a hydroxyl group, or a carbon number of 1 to 6). One or two or more substituents selected from the group consisting of an alkylthio group and an alkoxy group having 1 to 6 carbon atoms are one or two substituents (the same or different if two) The amine moiety can be protected by a protecting group which is usually used. The above aryl group has a carbon number of 6 to 10, and the heteroaryl group is a 5-membered ring or a 6-membered ring, and may have one to four heterogeneously selected from a nitrogen atom, an oxygen atom and a sulfur atom. The above aryl and heteroaryl groups may have a halogen atom, a hydroxyl group, a thiol group, an amine group, a nitro group, a cyano group, a carboxyl group, an aminomethyl group, a phenyl group, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 1. ~6 alkoxy group, carbon number 1 to 6 alkylthio group, carbon number 2 to 6 alkoxycarbonyl group, carbon number 2 to 5 fluorenyl group and heteroaryl group (5 member ring or 6 member ring, but 'A group having 1 to 4 hetero atoms selected arbitrarily selected from a nitrogen atom, an oxygen atom and a sulfur atom, or a substituent selected from the group consisting of an alkyl group, an alkoxy group, an alkylthio group, The alkoxycarbonyl group, the fluorenyl group, the phenyl group, and the heteroaryl group may be selected from the group consisting of a halogen atom, a hydroxyl group, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. The atom or the group is a substituent, and the amine group may further comprise a group consisting of a fluorenyl group, an alkyl group having 1 to 6 carbon atoms, a fluorenyl group having 2 to 5 carbon atoms, and an alkoxycarbonyl group having 2 to 5 carbon atoms. The 1 or 2 group selected by the group is a substituent. Any two of Rm, R14', R15, R16, and R16' may be integrally formed into a cyclic structure, and one or more hetero atoms selected arbitrarily from an oxygen atom, a nitrogen atom, and a sulfur atom may be a ring. atom. -23 - 200900066 The ring thus formed may have a halogen atom, a trans group, an amine group, an alkyl group having 1 to 6 carbon atoms, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. The group of atoms or groups selected by the group is a substituent, and the amine group may further have a methyl group, a carbon number of 1 to 6, an alkyl group having 2 to 5 carbon atoms, and an alkoxy group having 2 to 5 carbon atoms. The base of the group formed by the carbonyl group is selected to be a substituent or a formula (7)

[式中 R13、R13, 、R14、R14, 、R15、R16、R16, 、:R17 及 R17’爲前述Z所示雜環式取代基上之取代基。更具體而言 > R13及R13’各自獨立爲氫原子或碳數1〜6之烷基, 此烷基可有由鹵原子、羥基、胺基、胺甲醯基、碳數1 ~6 之烷硫基及碳數1〜6之烷氧基、碳數1~6之烷胺基、碳數 1〜6之鹵烷基及碳數1~6之胺烷基而成之群之基選擇之1 以上之基爲取代基。 式中R14、R14’ 、R15、R16及R16’各自獨立爲氫原子、 鹵原子、胺基、羥基、胺甲醯基、碳數1〜6之烷基、碳數 1~6之烷胺基、芳基、雜芳基、碳數1〜6之烷氧基、碳數 1~6之烷硫基、碳數丨~6之鹵烷基、或碳數1~6之胺烷基 > 上述烷基、烷硫基、鹵烷基、胺烷基及烷胺基之烷基部 分可有環狀構造,更可有由鹵原子、碳數;1~6之烷基、碳 -24- 200900066 數1~6之烷氧基而成之群選擇之1以上之原子或基爲取代 基。 又上述胺基、胺烷基及烷胺基之胺基部分可有碳數1〜6 之烷基(此烷基可有環狀構造,又可有由鹵原子、羥基、碳 數1~6之烷硫基及碳數1〜6之烷氧基而成之群選擇之1以 上之原子或基爲取代基)1個或2個爲取代基(若2個時可 相同或不同),此胺基部分更可以通常使用之保護基保護。 R17及R17’各自獨立爲氫原子、碳數1~6之烷基、芳基 、或雜芳基,此芳基爲碳數6~10、雜芳基爲5員環或6員 環,而可有1個~4個由氮原子、氧原子及硫原子任意選擇 之雜原子、 上述芳基及雜芳基可有由鹵原子、羥基、硫醇基、胺基 、硝基、氰基、羧基、胺甲醯基、苯基、碳數之烷基 、碳數1〜6之烷氧基、碳數1~6之烷硫基、碳數2〜6之烷 氧羰基、碳數2~5之醯基及雜芳基(5員環或6員環’而可 有1個~4個由氮原子、氧原子及硫原子任意選擇之雜原子 )而成之群選擇之1以上之原子或基爲取代基’ 其中之烷基、烷氧基、烷硫基、烷氧羰基、醯基、苯基 及雜芳基可有由鹵原子、羥基、碳數丨~6之烷氧基及碳數 1〜6之烷硫基而成之群選擇之1以上原子或基爲取代基’ 更胺基可有由甲醯基、碳數1~6之烷基、碳數2~5之酿基 及碳數2~5之烷氧羰基而成之群之基選擇之1或2基爲取 代基。 由上述、R14、R14, 、:R15、R16、R16’ 、:R17 及 R17,選擇 -25- 200900066 之任意2個可一體化形成環狀構造,而可有由氧原子、氮 原子、及硫原子任意選擇之1以上雜原子爲其環之構成原 子。 如此形成之環可有由鹵原子、羥基、胺基、碳數丨~6之 烷基、碳數1〜6之烷氧基及碳數1~6之烷硫基而成之群選 擇之1以上原子或基爲取代基,更此胺基可有由甲醯基、 碳數1~6之烷基、碳數2~5之醯基及碳數2~5之烷氧羰基 而成之群之基選擇之1或2基爲取代基] (、 若取代基Z以更具體構造式表示,則可列示如下取代基 ,但不受這些限定。又這些取代基中有不對稱碳而成爲光 學活性時,光學活性取代基當然含於Z。 -26- 200900066[wherein R13, R13, R14, R14, R15, R16, R16, and R17 and R17' are the substituents on the heterocyclic substituent represented by the above Z. More specifically, R13 and R13' are each independently a hydrogen atom or an alkyl group having 1 to 6 carbon atoms, and the alkyl group may have a halogen atom, a hydroxyl group, an amine group, an amine methyl group, and a carbon number of 1 to 6. Group selection of alkylthio groups and alkoxy groups having 1 to 6 carbon atoms, alkylamino groups having 1 to 6 carbon atoms, haloalkyl groups having 1 to 6 carbon atoms and amine alkyl groups having 1 to 6 carbon atoms The base of 1 or more is a substituent. Wherein R14, R14', R15, R16 and R16' are each independently a hydrogen atom, a halogen atom, an amine group, a hydroxyl group, an amine carbenyl group, an alkyl group having 1 to 6 carbon atoms, and an alkylamino group having 1 to 6 carbon atoms. , an aryl group, a heteroaryl group, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, a haloalkyl group having a carbon number of 1-6 or an alkyl group having a carbon number of 1 to 6 > The alkyl moiety of the above alkyl group, alkylthio group, haloalkyl group, amine alkyl group and alkylamino group may have a cyclic structure, and may further have a halogen atom, a carbon number, an alkyl group of 1 to 6, and a carbon-24-. 200900066 A group of 1 or more atoms or groups selected from the group consisting of alkoxy groups of 1 to 6 is a substituent. Further, the amine group of the above amine group, amine alkyl group and alkylamino group may have an alkyl group having 1 to 6 carbon atoms (the alkyl group may have a cyclic structure, or may have a halogen atom, a hydroxyl group, or a carbon number of 1 to 6). One or two or more substituents selected from the group consisting of an alkylthio group and an alkoxy group having 1 to 6 carbon atoms are one or two substituents (the same or different if two) The amine moiety can be protected by a protecting group which is usually used. R17 and R17' are each independently a hydrogen atom, an alkyl group having 1 to 6 carbon atoms, an aryl group or a heteroaryl group, and the aryl group is a carbon number of 6 to 10, and the heteroaryl group is a 5-membered ring or a 6-membered ring. There may be one to four hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and the above aryl group and heteroaryl group may have a halogen atom, a hydroxyl group, a thiol group, an amine group, a nitro group, a cyano group, a carboxyl group, an amine carbenyl group, a phenyl group, an alkyl group having a carbon number, an alkoxy group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, an alkoxycarbonyl group having 2 to 6 carbon atoms, and a carbon number of 2~ A group of 5 or more atoms selected from the group consisting of a sulfhydryl group and a heteroaryl group (a 5-membered ring or a 6-membered ring and having 1 to 4 hetero atoms selected arbitrarily by a nitrogen atom, an oxygen atom, and a sulfur atom) Or a substituent: wherein the alkyl group, the alkoxy group, the alkylthio group, the alkoxycarbonyl group, the fluorenyl group, the phenyl group and the heteroaryl group may have a halogen atom, a hydroxyl group, an alkoxy group having a carbon number of 丨6 and The group of the alkylthio group having 1 to 6 carbon atoms is selected from the group consisting of 1 or more atoms or the substituent is a substituent. The more amine group may have a methyl group, an alkyl group having 1 to 6 carbon atoms, and a carbon number of 2 to 5. One or two bases selected from the group consisting of alkoxycarbonyl groups having 2 to 5 carbon atoms Substituents. From the above, R14, R14, , R15, R16, R16', R17 and R17, any two of -25-200900066 may be selected to form a cyclic structure, and may have an oxygen atom, a nitrogen atom, and sulfur. Any one or more of the atoms selected by the atom is a constituent atom of the ring. The ring thus formed may have a group selected from the group consisting of a halogen atom, a hydroxyl group, an amine group, an alkyl group having a carbon number of 66, an alkoxy group having 1 to 6 carbon atoms, and an alkylthio group having 1 to 6 carbon atoms. The above atom or group is a substituent, and the amine group may have a group consisting of a fluorenyl group, an alkyl group having 1 to 6 carbon atoms, a fluorenyl group having 2 to 5 carbon atoms, and an alkoxycarbonyl group having 2 to 5 carbon atoms. The substituent 1 or 2 is selected as a substituent] (If the substituent Z is represented by a more specific structural formula, the following substituents may be listed, but are not limited thereto. Further, these substituents have an asymmetric carbon and become Optically active substituents are of course contained in Z when optically active. -26- 200900066

添加醇而安定化之本發明之水性製劑中,作爲活性成分 含有之式(1)喹喏酮系合成抗菌化合物,可爲Z所示7位之 取代基爲上述式(4)、(5)、(6)及(7)之喹喏酮化合物。也即 可得這些取代基之特徵之具有一級胺基之7位取代基之喹 喏酮化合物中安定化效果高之水性製劑。 -27- 200900066 這些化合物可於調製水性製劑之際,作爲原料使用其鹽 及/或彼等之水合物。喹喏酮化合物之配合量依存於個別之 溶解度,只要爲溶解度以内之配合量則無特限,可例如 1.0~5.0mg/mL 之範圍。 添加本發明之水性製劑之醇類可使用種種醇化合物。例 如碳數1 ~6之脂肪族醇類及苄醇。又脂肪族醇以1價、2 價、及3價者較佳,也可用其以上之多價醇。這些例可爲 甲醇、乙醇、1-丙醇、2-丙醇、1-丁醇、2-丁醇、2-甲基-(] 2-丙醇、2-甲基-1-丙醇、苄醇等1價醇;乙二醇、丙二醇 等2價醇;甘油等多價醇。這些醇化合物中以乙醇、乙二 醇、丙二醇、甘油及苄醇較佳,尤宜乙醇及甘油。又這些 醇化合物可個別單獨或複數之組合使用。醇化合物之配合 量只要爲0.5w/v%以上,尤宜0.5~10w/v%之範圍。 ' 本發明之水性注射劑之pH爲3〜8之範圍,尤宜3~6之範 圍。 於本發明之水性液劑、依必要而適宜添加pH調節劑、等 ί : 張化劑等。pH調節劑可爲例如鹽酸、硫酸、磷酸等無機酸 類;碳酸鈉、碳酸氫鈉、磷酸氫鈉、磷酸二氫鈉等無機酸 鹽類;乙酸、乳酸、檸檬酸' 酒石酸、甲磺酸等有機酸類 :檸檬酸鈉、乳酸鈉、乙酸鈉等有機酸鹽類;氫氧化鈉等 無機鹽類等。 等張化劑可爲例如氯化鈉、氯化鎂、氯化鈣、氯化鐵等 無機鹽類;硫酸鎂、硫酸鈣等無機酸鹽類;葡萄糖、精製 白糖、聚葡萄糖等糖類;D-山梨糖醇、甘露糖醇、肌醇等 -28- 200900066 糖醇類。 本發明之水性注射劑之製造可依通常實施之水性注射劑 之製造方法實施。也即,將喹喏酮化合物、醇化合物、其 他添加劑於注射用水以適當順序添加而溶解。更依必要而 添加pH調節劑來調整pH,作成水性製劑。如上調製之水 性製劑可依過濾滅菌濾器來過濾或高壓蒸氣滅菌等通常之 方法而滅菌。水性製劑也可滅菌後充塡於容器,於容器充 塡後施行滅菌操作。In the aqueous preparation of the present invention which is stabilized by the addition of an alcohol, the quinacridone-based synthetic antibacterial compound of the formula (1) which is contained as an active ingredient, and the substituent at the 7-position represented by Z are the above formulas (4) and (5). , (6) and (7) quinacridone compounds. Further, an aqueous preparation having a high stabilization effect in the quinacridone compound having a substituent at the 7-position of the primary amino group which is characteristic of these substituents can be obtained. -27- 200900066 These compounds can be used as a raw material for the preparation of aqueous preparations, and as their raw materials, their salts and/or their hydrates. The compounding amount of the quinophthalone compound depends on the individual solubility, and is not particularly limited as long as it is within the solubility, and may be, for example, in the range of 1.0 to 5.0 mg/mL. Various alcohol compounds can be used for the alcohol to which the aqueous preparation of the present invention is added. For example, aliphatic alcohols having 1 to 6 carbon atoms and benzyl alcohol. Further, the aliphatic alcohol is preferably one-valent, two-valent, and three-valent, and a polyvalent alcohol of the above may be used. These examples may be methanol, ethanol, 1-propanol, 2-propanol, 1-butanol, 2-butanol, 2-methyl-(] 2-propanol, 2-methyl-1-propanol, a monovalent alcohol such as benzyl alcohol; a divalent alcohol such as ethylene glycol or propylene glycol; or a polyvalent alcohol such as glycerin. Among these alcohol compounds, ethanol, ethylene glycol, propylene glycol, glycerin and benzyl alcohol are preferred, and ethanol and glycerin are particularly preferred. These alcohol compounds may be used singly or in combination of a plurality of them. The compounding amount of the alcohol compound is preferably 0.5 w/v% or more, particularly preferably 0.5 to 10 w/v%. The pH of the aqueous injection of the present invention is 3 to 8 The range is particularly preferably in the range of 3 to 6. In the aqueous liquid preparation of the present invention, a pH adjuster or the like is added as needed, and the pH adjuster may be an inorganic acid such as hydrochloric acid, sulfuric acid or phosphoric acid; Inorganic acid salts such as sodium carbonate, sodium hydrogencarbonate, sodium hydrogen phosphate, sodium dihydrogen phosphate; organic acids such as acetic acid, lactic acid, citric acid, tartaric acid, methanesulfonic acid, etc.: organic acid salts such as sodium citrate, sodium lactate, sodium acetate An inorganic salt such as sodium hydroxide, etc. The isotonic agent may be an inorganic salt such as sodium chloride, magnesium chloride, calcium chloride or iron chloride. Inorganic acid salts such as magnesium sulfate and calcium sulfate; sugars such as glucose, refined white sugar, and polydextrose; D-sorbitol, mannitol, inositol, etc. -28-200900066 Sugar alcohols. The production method can be carried out according to a method for producing an aqueous injection which is usually carried out, that is, a quinophthalone compound, an alcohol compound, and other additives are added in an appropriate order to dissolve the water for injection, and a pH adjuster is added as necessary to adjust the pH. The aqueous preparation can be sterilized by a usual method such as filtration or high-pressure steam sterilization according to a filter sterilization filter. The aqueous preparation can also be sterilized and filled in a container, and then sterilized after the container is filled.

(實施例) 以下列示實施例更詳細説明本發明,但本發明不受這些 限定,任何意義中這些不爲限定解釋。(Examples) The present invention is illustrated in more detail by the following examples, but the invention is not limited thereto, and these are not to be construed as limiting.

這些實施例中使用之化合物1 ~4之構造如下:The structures of compounds 1 to 4 used in these examples are as follows:

[實施例1〜3] 實施例1 ~ 3之處方如表1。 於生理食鹽液(〇 · 9 %氣化鈉水溶液)1,8 〇 〇 m L添加1 m ο 1 / L 鹽酸25mL、化合物1之原藥i〇,66g(按無水物i〇g)而溶解 -29- 200900066 後’添加0.1mol/L氫氧化鈉水溶液而調節爲ph4.0後,更 添加生理食鹽液而調整液量爲2,000mL,作爲化合物1之 母液。於此母液2 0 0 m L添加混合無水乙醇9,3 7 5 m g或濃甘 油32.5g或丙二醇4,125mg,更添加生理食鹽液,個別液量 調整爲25OmL。此液以0.22 // m之濾器過濾後,於聚乙烯 製塑膠瓶充塡50mL,於102°C加熱滅菌60分。 【表1】[Examples 1 to 3] Examples 1 to 3 are as shown in Table 1. Add 1 m ο 1 / L hydrochloric acid 25 mL to the physiological saline solution (〇· 9 % sodium carbonated water solution), and dissolve the original drug i〇, 66 g (as anhydrous i〇g). -29- 200900066 After the addition of a 0.1 mol/L sodium hydroxide aqueous solution to adjust to ph4.0, a physiological saline solution was further added to adjust the amount of liquid to 2,000 mL, which was used as a mother liquid of Compound 1. To the mother liquor of 200 ml, mixed anhydrous ethanol 9,3 7 5 m g or concentrated glycerin 32.5 g or propylene glycol 4,125 mg, and a physiological saline solution was added, and the individual liquid amount was adjusted to 25 OmL. The solution was filtered through a 0.22 // m filter, filled in a polyethylene plastic bottle with 50 mL, and heat-sterilized at 102 ° C for 60 minutes. 【Table 1】

成分- 實施例1 實施例2 實施例3 化雜1 2 13.2 mg 2 13.2 mg 2 13. 2 mg (按無水物) (200 mg) (200 mg) (200 mg) 氯化鈉 4 5 0 mg 4 5 0 mg 4 5 0 mg 無水乙醇 1,875 mg — 一 濃甘油 — 6,500 mg 一 丙二醇 一 一 8 2 5 mg 鹽酸 適It (pH4. 0) 適置(pH4. 0) 適置(pH4. 0) 氫氧化鈉 適置(ρΗ4· 0) 適置(PH4. 0) 適量(ρΗ4· 0) 注射用水 全置5 OmL 全量5 OmL 全置5 Om LIngredients - Example 1 Example 2 Example 3 Compound 1 2 13.2 mg 2 13.2 mg 2 13. 2 mg (as anhydrous) (200 mg) (200 mg) (200 mg) Sodium chloride 4 5 0 mg 4 5 0 mg 4 5 0 mg Anhydrous ethanol 1,875 mg - One concentrated glycerol - 6,500 mg of 1-propylene glycol - 8 2 5 mg Hydrochloric acid suitable (It is pH 4. 0) Suitable (pH 4. 0) Suitable (pH 4. 0) Hydroxide Sodium suitable (ρΗ4· 0) Appropriate (PH4.0) Appropriate amount (ρΗ4· 0) Water for injection 5 OmL Total 5 OmL Full 5 Om L

[對照例1] 對照例1之處方如表2。 採集實施例1 ~ 3之化合物1之母液2 OOmL,添加生理食 鹽液而調整液量爲250mL。此液以0.22// m之瀘器過濾後 ,於聚乙烯製塑膠瓶充塡5 OmL,於102 °C加熱滅菌60分 【表2】[Comparative Example 1] The contents of Comparative Example 1 are shown in Table 2. The mother liquor of the compound 1 of Examples 1 to 3 was collected in 200 mL, and the physiological saline solution was added to adjust the amount of the solution to 250 mL. The solution was filtered through a 0.22/m m crucible, filled with 5 OmL in a polyethylene plastic bottle, and heat-sterilized at 102 °C for 60 minutes [Table 2]

成分 對照例1 化合物1 (按無水物) 2 13. 2 mg (2 0 0 mg) 氯化鈉 4 5 0 mg 鹽酸 適量(ρΗ4· 0) 氫氧化鈉 速置(ρΗ4. 0) 注射用水 全 ft 5 0 m LIngredient Comparative Example 1 Compound 1 (as anhydrate) 2 13. 2 mg (200 mg) Sodium chloride 4 5 0 mg Hydrochloric acid (ρΗ4·0) Sodium hydroxide (ρΗ4.0) Water for injection ft 5 0 m L

[試驗例1] -30- 200900066 將實施例1〜3及對照例1之製劑於80°C保存5日,評價 保存後之外觀及不溶性微粒子。外觀依目視觀察,不溶性 微粒子依日本藥典一般試驗法之顯微鏡法測定。結果如表 3。與對照例1之藥液中之不溶性微粒子數比較,於實施 例1〜3之藥液不溶性微粒子數少,確認因醇類之添加而抑 制不溶性微粒子之生成。 【表3】 檢體 外觀 不溶性微粒子 1 0 jU m以上 (個/m L) 2 5 m以上 實施例1 黄色 0. 03 0.0 2 實施例2 黄色 0. 19 0. 09 寅施例3 黄色 0. 60 0. 28 對照例4 黄色 0. 99 0. 59 [實施例4~15] 實施例4~15之處方如表4及表5。 於注射用水450mL添加lmol/L鹽酸6.25mL、化合物1之 原藥2.665g(按無水物2.5g)而溶解後,添加O.lmol/L氫氧 化鈉水溶液而調節爲pH4.0後,更添加注射用水而調整液 量爲500mL ’作爲化合物1之母液。於此母液20mL添加 混合各醇1 · 2 5 g,更添加注射用水,個別液量調整爲2 5 m L 。此液以0.22 /z m之濾器過濾後,於聚丙烯製試驗管分注 1 OmL 〇 -31 - 200900066[Test Example 1] -30-200900066 The preparations of Examples 1 to 3 and Comparative Example 1 were stored at 80 ° C for 5 days, and the appearance and insoluble fine particles after storage were evaluated. The appearance was visually observed, and the insoluble microparticles were measured by the microscopic method of the Japanese Pharmacopoeia general test method. The results are shown in Table 3. In comparison with the number of insoluble fine particles in the chemical solution of Comparative Example 1, the number of insoluble fine particles in the chemical solutions of Examples 1 to 3 was small, and it was confirmed that the formation of insoluble fine particles was suppressed by the addition of alcohol. [Table 3] Sample appearance insoluble fine particles 1 0 jU m or more (pieces/m L) 2 5 m or more Example 1 Yellow 0. 03 0.0 2 Example 2 Yellow 0. 19 0. 09 寅 Example 3 Yellow 0. 60 0. 28 Comparative Example 4 Yellow 0. 99 0. 59 [Examples 4 to 15] Examples 4 to 15 are shown in Tables 4 and 5. After adding 4.55 mL of 1 mol/L hydrochloric acid and 2.665 g of the original drug of Compound 1 (2.5 g of anhydrate) to 450 mL of water for injection, the solution was dissolved in an aqueous solution of 0.1 mol/L sodium hydroxide and adjusted to pH 4.0, and then added. The amount of the solution was adjusted to 500 mL of water for injection as the mother liquor of Compound 1. To the mother liquor of 20 mL, 1 · 2 5 g of each alcohol was added, and water for injection was further added, and the amount of each liquid was adjusted to 2 5 m L . This solution was filtered through a 0.22 /z m filter and dispensed in a polypropylene test tube 1 OmL 〇 -31 - 200900066

CC

-32- 200900066-32- 200900066

-33 - 200900066 [對照例2] 採集實施例4~ 15所示化合物1之母液 用水來調整液量爲25mL。此液以0.22 M m 於聚丙烯製試驗管分注10mL。 [試驗例2] 將實施例4〜15及對照例2之製劑於8(TC 後之藥液10mL以0.45 /zm之膜濾器過滤 光學顯微鏡(倍率1 00倍)觀察。濾器過濾 〇 如第1圖。 於對照例2,因多數不溶性微粒子使濾 但於實施例4〜15之濾器過濾面,起因於 著色減低,而確認微粒子數少。由以上結 制效果於其他醇類也得確認。 ' [實施例1 6 ~ 21 ] 實施例16〜21之處方如表6。 調製以鹽酸及氫氧化鈉調整pH爲3.0〜4 / 化合物2之水溶液。於此液5mL添加混合 2 · 5 g、5.0 g,更添力α注射用水而調整個另[]名 樣於化合物2之水溶液5 m L添加混合濃卞 5.0 g,更添加注射用水來調整個別液量爲 以0.22;zm之濾器過濾後,於聚乙烯製塑 20mL,添加注射 之濾器過濾後, 保存5日。保存 ,濾器過濾面以 面之顯微鏡照片 器著色爲褐色, 不溶性微粒子之 果,微粒子之抑 • 0 之 20mg/mL 之 •無水乙醇l.Og、 交量爲50mL。同 r 油 l.Og 、 2.5g 、 50mL。將這些液 膠瓶分注10mL。 -34- 200900066-33 - 200900066 [Comparative Example 2] The mother liquid of the compound 1 shown in Examples 4 to 15 was collected. The amount of the liquid was adjusted to 25 mL with water. This solution was dispensed to 10 mL in a polypropylene test tube at 0.22 M m. [Test Example 2] The preparations of Examples 4 to 15 and Comparative Example 2 were observed in an optical microscope (magnification: 100 times) of a membrane filter of 0.45 /zm at 8 mL (10 mL of the drug solution after TC). In Comparative Example 2, most of the insoluble fine particles were filtered, but on the filter surface of Examples 4 to 15, the number of fine particles was small due to the decrease in coloration. The above-mentioned effect was confirmed in other alcohols. [Example 1 6 to 21] The results of Examples 16 to 21 are shown in Table 6. The pH of the solution was adjusted to 3.0 to 4 / Compound 2 with hydrochloric acid and sodium hydroxide, and 5 mL of this solution was added and mixed 2 · 5 g, 5.0 g, more force α water for injection and adjust another [] name in the aqueous solution of compound 2 5 m L added mixed concentrated 5.0 g, add water for injection to adjust the amount of individual liquid to 0.22; zm filter, 20mL of polyethylene plastic, filtered with an injection filter, and stored for 5 days. Preserved, the filter surface is colored brown by the microscopic photo of the surface, the fruit of the insoluble microparticles, the microparticles of the 20mg/mL of water. Ethanol l.Og, the amount of 50mL. Same r oil l.Og, 2.5g, 50mL. Dispense these liquid bottles into 10mL. -34- 200900066

CD 撇CD 撇

-35 - 200900066 [對照例3] 調製以鹽酸及氫氧化鈉調整pH爲3.0 化合物2之水溶液。於此液5mL添加柱 爲50mL。此液以0.22/z m之濾器過濾孩 瓶分注1 0 m L。 [試驗例3] 將實施例16~21及對照例3之製劑於 價保存後之不溶性微粒子。不溶性微粒 f 般試驗法之顯微鏡法測定。結果如表7 與對照例3之藥液中之不溶性微粒3 1 6〜2 1之藥液確認不溶性微粒子數減低 添加醇類之不溶性微粒子之抑制效果, 製劑也得確認。 ~4.0 之 20mg/mL 之 :射用水來調整液量 :,於聚乙烯製塑膠 80°C保存5日,評 子乃依日本藥典一 〇 數比較,於實施例 。由以上結果,因 於含有化合物2之 -36- 200900066 【z嗽】 g -Μ ε 3 \ ε S ^ ΙΟ Ν 屮 U 1 00 d CSJ 寸 〇 <0 截 您d K·穴 激% m I < ο P - § 1 to csi 寸 csi r- r— 檢體 1 「實施例19 實施例20 窜裤例21 ί粒子(e/mL) 2 5//ΓΤ1 以上 00 寸 〇 r· 寸 d 6 m 链 If ^ m fc ^ 〇 P - § 0) T— 寸 〇 甘 6 檢體 對照例3 實施例16 實施例17 實施例18 -37- 200900066 [實施例22] 實施例2 2之處方如表8。-35 - 200900066 [Comparative Example 3] An aqueous solution of Compound 2 having a pH of 3.0 adjusted with hydrochloric acid and sodium hydroxide was prepared. The 5 mL addition column of this solution was 50 mL. This solution was dispensed by a filter of 0.22/z m to dispense 10 m L of the baby. [Test Example 3] The insoluble fine particles of the preparations of Examples 16 to 21 and Comparative Example 3 were stored at a price. Insoluble microparticles were measured by microscopic method of the general test method. As a result, the chemical solution of the insoluble fine particles 3 16 to 2 1 in the chemical solution of Table 7 and Comparative Example 3 confirmed that the number of insoluble fine particles was reduced, and the inhibitory effect of the insoluble fine particles added with the alcohol was confirmed. ~4.0 of 20mg/mL: Water is used to adjust the amount of liquid: It is stored in polyethylene plastic at 80 °C for 5 days, and the evaluation is based on the Japanese Pharmacopoeia. From the above results, due to the inclusion of compound 2 -36- 200900066 [z嗽] g -Μ ε 3 \ ε S ^ ΙΟ Ν 屮 U 1 00 d CSJ inch 〇 <0 cut your d K · acupoint % m I < ο P - § 1 to csi inch csi r- r - Sample 1 "Example 19 Example 20 窜 裤 21 ί particles (e / mL) 2 5 / / ΓΤ 1 or more 00 inch 〇 r · inch d 6 m chain If ^ m fc ^ 〇P - § 0) T-inch 〇 Gan 6 sample Comparative Example 3 Example 16 Example 17 Example 18 -37- 200900066 [Example 22] Example 2 8.

調製含有化合物3(按無水物)5mg/mL、D-山梨糖醇 50mg/mL、氯化鎂6水合物〇.4mg/m:L、無水乙醇5〇mg/mL ’而以硫酸及氫氧化鈉調整pH爲4.5之水溶液。此液以 0.22 // m之爐器過濾後,於聚乙烯製塑膠瓶分注2〇mL。The preparation contains compound 3 (as anhydrous) 5 mg / mL, D-sorbitol 50 mg / mL, magnesium chloride 6 hydrate 〇 4 mg / m: L, absolute ethanol 5 〇 mg / mL ' and adjusted with sulfuric acid and sodium hydroxide An aqueous solution having a pH of 4.5. This solution was filtered through a 0.22 // m furnace and dispensed in a polyethylene plastic bottle of 2 〇 mL.

成份 實施例2 2 化合物3 10 2. 14 mg (按無水物) (10 0 mg) D-山梨糖醇 -- 1 . 0 g 氯化鎂6水合物 〜- 8.0 mg 無水乙醇 1.0 κ 硫酸 … 逋量(ρΗ4· 5) 氫氧化鈉 »Λ (ρΗ4. 5) 注射用水 全S20 mLIngredient Example 2 2 Compound 3 10 2. 14 mg (as anhydrous) (10 0 mg) D-sorbitol - 1.0 g Magnesium chloride 6 hydrate ~- 8.0 mg Anhydrous ethanol 1.0 κ Sulfuric acid... Η4· 5) Sodium hydroxide»Λ (ρΗ4. 5) Water for injection S20 mL

[對照例4] 對照例4之處方如表9。 調製含有化合物3(按無水物)5mg/mL、D-山梨糖醇 50mg/mL、氯化鎂6水合物〇.4mg/mL,而以硫酸及氫氧化 鈉調整pH爲4.5之水溶液。此液以0.22# m之濾器過濾後 ’於聚乙燃製塑膠瓶分注L。 【表9】[Comparative Example 4] The contents of Comparative Example 4 are shown in Table 9. An aqueous solution containing 5 mg/mL of the compound 3 (as an anhydride), 50 mg/mL of D-sorbitol, and 4 mg/mL of magnesium chloride hexahydrate was prepared, and the pH was adjusted to 4.5 with sulfuric acid and sodium hydroxide. This solution was filtered through a 0.22 # m filter and dispensed in a polyethylene-fired plastic bottle. [Table 9]

成份 對照例4 化合物3 10 2. 14 mg (按無水物) (10 0 mg) D-山梨糖醇 1.0 g 氯化鎂6水合物 8. 0 mg 適置(pH4. 5) 氫氧化鈉 適置(pH4. 5) 注射用水 - 全置20 mL -38- 200900066 [試驗例4] 將實施例22及對照例4之製劑於80°C保存1 〇日’評價 保存後之不溶性微粒子。不溶性微粒子乃依日本藥典一般 試驗法之顯微鏡法測定。結果如表1 〇。 與對照例4之藥液中之不溶性微粒子數比較’於實施例 22之藥液確認不溶性微粒子數減低。由以上結果’添加醇 類之不溶性微粒子之抑制效果,於含有化合物3之製劑也 得確認。又不溶性微粒子之抑制效果,確認比添加糖醇類 Γ' 之處方有利。 【表1〇】 檢體 801/10日後不溶 10#m以上 性微粒子(fi/mL) 2 5"m以上 實施例2 0. 1 0. 0 對照例4 2. 3 0. 5 [實施例23~28] 實施例23〜28之處方如表11。 將化合物4之原藥2,268mg(按自由體爲2,000mg)溶解於 注射用水後,更添加注射用水作成200mL。於此液20mL 添加混合無水乙醇l.Og、2.5g、5.0g,更添加注射用水來 調整個別液量爲5 0 m L。同樣於化合物4之水溶液2 0 m L添 加混合濃甘油l.Og、2.5g、5.0g,更添加注射用水來調整 個別液量爲50mL。這些液以0.22 /i m之濾器過濾後,於聚 乙烯製塑膠瓶分注lOmL。 -39- 200900066 【Γ—Iτ撇】 實施例28 4 5. 3 6 mg (4 0 mg) 1 1 000 m s 全ft1OmL 實施例27 4 5. 3 6 mg (4 0 mg) 1 ' 500 mg 全量1 0 m L 實施例26 4 5. 3 6 mg (4 0 mg) 1 1 200 mg 全置1 0 m L 實施例25 4 5. 3 6 mg (4 0 mg) 1000 mg 1 全邐;10m L 實施例24 4 5.36 mg (4 0 ms) 5 0 0 mg 1 全置1 Om L 實施例23 4 5. 3 6 ms (4 0 mg) 2 0 0 mg ! 全量1OmL 成份 化合物4 (按自由體) 無水乙醇 濃甘油 注射用水 -40- 200900066 [對照例5] 將化合物4之原藥2,268mg(按自由體爲2,000mg)溶解於 注射用水後,更添加注射用水爲200mL。於此液20mL添 加注射用水來調整液量爲50mL。此液以0.22 g m之濾器過 濾後,於聚乙烯製塑膠瓶分注l〇mL。 [試驗例5] 將實施例23〜28及對照例5之製劑於80°C保存10日,評 價保存後之不溶性微粒子。不溶性微粒子乃依日本藥典一 (' 般試驗法之顯微鏡法測定。結果如表1 2。 與對照例5之不溶性微粒子數比較’於實施例23〜28之 藥液確認不溶性微粒子數減低。由以上結果’因添加醇類 之不溶性微粒子之抑制效果,於含有化合物4之製劑也得 . 確認。 -41 - 200900066 /E%^ 【2 T漱】 <«—s ^ i si in 屮 «Μ 藜 4+4 1 0) d d (D to ϋ 琺 Κ- 游^ tn is 〇 ε ρ ° § ^ 1 CO CM 对 CSJ 0) 寸 r- 檢體 1 實施例26 實施例27 00 CN 匡 辑 魏 i Μ s 1 10 屮 «Μ 藜 卜 CM τ— Ο d Ο d 键 If 班-Μ m ϊ} s 1 Ρ ο § - σ> 寸 0) CO 04 6 ο d 檢體 對照例5 m CM 匡 辑 |ι 實施例24 實施例25 -42- 200900066 [實施例29~34] 實施例29〜34之處方如表13 ^ 於注射用水添加化合物1之原藥後,更添加1 mol/L鹽酸 來溶解後,添加〇.lmol/L鹽酸或O.lmol/L氫氧化鈉來調整 pH爲4.0後,添加混合無水乙醇或濃甘油成各濃度,更添 加注射用水來施行液量調整。此液以0.22 // m之濾器過濾 後,於Non-PVC製塑膠包分注50mL。分注後’由鋁箔包 施行2次包裝後,於1 2 1 °C施行滅菌30分。Ingredient Comparative Example 4 Compound 3 10 2. 14 mg (as anhydrous) (10 0 mg) D-sorbitol 1.0 g Magnesium chloride 6 hydrate 8. 0 mg Suitable (pH 4.5) Sodium hydroxide (pH 4) 5) Water for injection - 20 mL of total - 38 - 200900066 [Test Example 4] The preparations of Example 22 and Comparative Example 4 were stored at 80 ° C for 1 ' day to evaluate the insoluble fine particles after storage. The insoluble fine particles were determined by a microscopic method in accordance with the general test method of the Japanese Pharmacopoeia. The results are shown in Table 1. Comparison with the number of insoluble fine particles in the chemical solution of Comparative Example 4 The chemical liquid of Example 22 was confirmed to have a reduced number of insoluble fine particles. From the above results, the inhibitory effect of the addition of the insoluble fine particles of the alcohol was confirmed in the preparation containing the compound 3. Further, the inhibitory effect of the insoluble fine particles was confirmed to be advantageous over the prescription of adding the sugar alcohol Γ'. [Table 1〇] The sample was insoluble in 10#m or more fine particles (fi/mL) after 801/10 days. 2 5"m or more Example 2 0. 1 0. 0 Comparative Example 4 2. 3 0. 5 [Example 23 ~28] Examples 23 to 28 are as shown in Table 11. 2,268 mg of the original drug of Compound 4 (2,000 mg in free form) was dissolved in water for injection, and 200 mL of water for injection was added thereto. 20 mL of this solution was added with 1.0 g of anhydrous ethanol, 2.5 g, and 5.0 g, and water for injection was added to adjust the amount of the individual liquid to 50 ml. Similarly, an aqueous solution of Compound 4 was added at a concentration of 20. 0 g of concentrated glycerin, 2.5 g, 5.0 g, and water for injection was added to adjust the amount of the individual liquid to 50 mL. These liquids were filtered through a 0.22 /i m filter and dispensed in a polyethylene plastic bottle. -39- 200900066 [Γ-Iτ撇] Example 28 4 5. 3 6 mg (40 mg) 1 1 000 ms Full ft1OmL Example 27 4 5. 3 6 mg (40 mg) 1 '500 mg Full amount 1 0 m L Example 26 4 5. 3 6 mg (40 mg) 1 1 200 mg Fully 10 m L Example 25 4 5. 3 6 mg (40 mg) 1000 mg 1 full hydrazine; 10 m L Example 24 4 5.36 mg (40 ms) 5 0 0 mg 1 Full set 1 Om L Example 23 4 5. 3 6 ms (40 mg) 2 0 0 mg ! Total amount 1OmL Ingredient compound 4 (free body) Anhydrous Ethanol concentrated glycerin water for injection-40-200900066 [Comparative Example 5] 2,268 mg of the original drug of Compound 4 (2,000 mg in free form) was dissolved in water for injection, and 200 mL of water for injection was further added. 20 mL of this solution was added with water for injection to adjust the amount of the solution to 50 mL. The solution was filtered through a 0.22 g filter and dispensed in a polyethylene plastic bottle. [Test Example 5] The preparations of Examples 23 to 28 and Comparative Example 5 were stored at 80 ° C for 10 days, and the insoluble fine particles after storage were evaluated. The insoluble fine particles were determined according to the Japanese Pharmacopoeia 1 (the microscopic method of the general test method. The results are shown in Table 12. The comparison with the number of insoluble fine particles of Comparative Example 5) The chemical solutions of Examples 23 to 28 were confirmed to have a reduced number of insoluble fine particles. 'The inhibitory effect of the insoluble fine particles added with alcohol is also obtained in the preparation containing the compound 4. Confirmation. -41 - 200900066 /E%^ [2 T漱] <«-s ^ i si in 屮«Μ 藜4 4 D D D D D D 1 10 屮«Μ 藜 CM τ— Ο d Ο d key If class-Μ m ϊ} s 1 Ρ ο § - σ> inch 0) CO 04 6 ο d sample control example 5 m CM 匡 | ι Example 24 Example 25 - 42 - 200900066 [Examples 29 to 34] Examples 29 to 34 are as shown in Table 13 ^ After adding the original drug of Compound 1 to water for injection, 1 mol/L hydrochloric acid was added to dissolve, and then added. 〇.lmol/L hydrochloric acid or O.lmol/L sodium hydroxide to adjust the pH to 4.0, add mixed absolute ethanol or concentrated glycerol to each concentration, and add for injection. Water is used to adjust the liquid volume. The solution was filtered through a 0.22 // m filter and dispensed in a Non-PVC plastic bag of 50 mL. After the dispensing, the package was applied twice in aluminum foil and sterilized at 31 °C for 30 minutes.

U -43- 200900066 -/^ 【COI嗽】 實施例3 4 10 6. 6 mg (100 mg) 1 ※日 適置(pH4_ 0) 寸 X a m m -j E 〇 to m 實施例3 3 10 6.6 mg (10 0 mg) «3 1 實施例3 2 15 9. 9 mg (15 0 mg) 1 ※斗 rH CO m 辑 κ 15 9. 9 mg (15 0 mg) 糸3 1 ο CO 辑 K 2 13. 2 mg (2 0 0 mg) 1 浓2 σ> (Μ 辑 in 2 13.2 mg · (2 0 0 mg) 1 成分 化合物1 (按無水物) 無水乙醇 濃甘油 鹽酸 氫氧化鈉 注射用水 ^o.2o_so«,ol ,sd,Id,od滩埘鄉^腾链^腾!»※ yoloI—lo.go.so.CSIo.T ,s ·0,0·0 滩埘«异腾银导)!寸※ yoo.s ,ο.εο.ζο.τ ,so00滩埘鹅异验嗯^^妁※ %ο·2ο·9ο·ε ,Ο.ΖΟΊ ,90,1.0 ,00滩埘鹅a-R腾堪导^^※ O/OO.SOCOO.ZO.T ,so,ΙΌΟΌ 滩埘鹅另腾链^腾!.※ -44- 200900066 [試驗例6] 將實施例29〜34之製劑於80°C保存5日,評價保存後之 不溶性微粒子。不溶性微粒子乃依日本藥典一般試驗法之 顯微鏡法測定。實施例29、31、33之測定結果如表14及 第2圖。於實施例29及31、乙醇無添加時,確認計數不 可能之多數存在之微粒子,隨乙醇添加量之增加而減少。 於實施例33也呈示同樣之傾向,因添加0.5%之乙醇,而 幾無法認定不溶性微粒子。 Γ" 實施例30、32、34之測定結果如表15及第3圖。於實 施例3 0及3 2、甘油無添加時,有計數不可能之多數存在 之微粒子隨添加量之增加而減少,於1 0 %之甘油添加再度 確認微粒子數增加之傾向。於實施例34也同樣,於1〜2% ' 之甘油添加幾無法認出之微粒子,因5~10%之添加而確認 若干增加之傾向。 -45 - 200900066 【表1 4】 檢體 無水乙醇 8 80^/5日後不溶性微粒子l/m L) 添加濃度 1 O/im以上 2 5 以上 0. 0% 多數882 多數” 0. 1% 多C2 多數《 0. 5% 11.00 6. 4 0 實施例2 9 1.0% 4.3 8 2. 7 8 2. 0% 3. 6 0 2. 00 3. 0% 4. 8 7 2. 3 2 5. 0% 0. 9 0 0. 3 5 0. 0% 多數《 多數θ 0. 5% 8. 0 5 4. 4 3 實施例3 1 1 . 0% 1.88 0. 6 3 2. 0% 1.15 0· 4 3 5. 0% 3. 2 3 1.58 0. 0% 3. 9 5 1.45 0. 5% 0. 4 3 0. 0 5 實施例3 1.0% 0. 0 5 0. 00 2. 0% 0. 3 3 0. 18 5. 0% 0. 03 0. 0 0U -43- 200900066 -/^ [COI嗽] Example 3 4 10 6. 6 mg (100 mg) 1 ※ Daily application (pH4_ 0) inch X amm -j E 〇to m Example 3 3 10 6.6 mg (10 0 mg) «3 1 Example 3 2 15 9. 9 mg (15 0 mg) 1 * bucket rH CO m series κ 15 9. 9 mg (15 0 mg) 糸3 1 ο CO series K 2 13. 2 mg (200 mg) 1 Concentration 2 σ> (Μ in in 2 13.2 mg · (200 mg) 1 Ingredient compound 1 (as anhydrate) Anhydrous ethanol concentrated glycerol Hydrochloric acid Sodium hydroxide water for injection ^o.2o_so «, ol, sd, Id, od beach township ^ Teng chain ^ Teng!»※ yoloI-lo.go.so.CSIo.T, s ·0,0·0 Beach 埘 « 异腾银导)! inch ※ Yoo.s , ο. εο. ζο.τ , so00 beach 埘 埘 验 ^ ^^妁 ※ %ο·2ο·9ο·ε , Ο.ΖΟΊ , 90,1.0 , 00 beach 埘 goose aR Tengkan guide ^^ ※ O/OO.SOCOO.ZO.T ,so,ΙΌΟΌ Beach geese another chain Teng! -4 - 200900066 [Test Example 6] The preparations of Examples 29 to 34 were stored at 80 ° C for 5 days, and the insoluble fine particles after storage were evaluated. The insoluble fine particles were determined by a microscopic method in accordance with the general test method of the Japanese Pharmacopoeia. The measurement results of Examples 29, 31 and 33 are shown in Table 14 and Figure 2. In Examples 29 and 31, when ethanol was not added, it was confirmed that the majority of the fine particles which were not counted were decreased as the amount of ethanol added was increased. The same tendency was exhibited in Example 33, and insoluble microparticles could not be identified by the addition of 0.5% of ethanol. Γ" The measurement results of Examples 30, 32, and 34 are shown in Table 15 and Figure 3. In the examples 30 and 3, when glycerin was not added, the number of fine particles which were not counted as a whole was decreased as the amount of addition was increased, and the addition of 10% of glycerin again confirmed the tendency of the number of fine particles to increase. In the same manner as in the example 34, a small amount of unrecognizable fine particles were added to the glycerin of 1 to 2%, and a tendency to increase was confirmed by the addition of 5 to 10%. -45 - 200900066 [Table 1 4] Sample anhydrous ethanol 8 80^/5 days after insoluble microparticles l/m L) Adding concentration 1 O/im or more 2 5 or more 0. 0% Most 882 majority" 0. 1% more C2 Most "0. 5% 11.00 6. 4 0 Example 2 9 1.0% 4.3 8 2. 7 8 2. 0% 3. 6 0 2. 00 3. 0% 4. 8 7 2. 3 2 5. 0% 0. 9 0 0. 3 5 0. 0% Most "Most θ 0. 5% 8. 0 5 4. 4 3 Example 3 1 1 . 0% 1.88 0. 6 3 2. 0% 1.15 0· 4 3 5. 0% 3. 2 3 1.58 0. 0% 3. 9 5 1.45 0. 5% 0. 4 3 0. 0 5 Example 3 1.0% 0. 0 5 0. 00 2. 0% 0. 3 3 0. 18 5. 0% 0. 03 0. 0 0

※1不溶性微粒子規格1 O/im以上:2fl/mL, 2 5/i m以上:盔2個/m L ※2有多數褐色凝膠狀異物狀,其數無法測定 -46 - 200900066 . 【表1 5】 檢體 無水乙醇 添加濃度 80t:/5日後不溶 1 以上 性微粒子(β/mL) 2 5//m以上装1 實施例2 9 0. 0% 多數《 多數"2 0. 1 % 多數※2 多數※2 0. 5% 11.00 6. 4 0 1. 0% 4.3 8 2.7 8 2. 0% 3.6 0 2. 00 3. 0% 4.8 7 2.3 2 5. 0% 0. 90 0. 3 5 實施例3 1 0. 0% 多數《 多數《 0. 5% 8. 0 5 4.4 3 1 . 0% 1.88 0.6 3 2. 0% 1.15 0.4 3 5. 0% 3.2 3 1.58 實施例3 3 0. 0% 3.9 5 1.45 0. 5% 0.4 3 0. 0 5 1 . 0% 0.0 5 0.0 0 2. 0% 0.3 3 0. 1 8 5. 0% 0. 03 0. 00*1 Insoluble fine particle size 1 O/im or more: 2fl/mL, 2 5/im or more: 2 helmets/m L *2 There are many brown gel-like foreign objects, and the number cannot be measured -46 - 200900066. [Table 1 5] The concentration of anhydrous ethanol added to the sample is 80t: 5 days after insoluble 1 or more microparticles (β/mL) 2 5//m or more 1 Example 2 9 0. 0% Most "Most" 2%. *2 Most ※2 0. 5% 11.00 6. 4 0 1. 0% 4.3 8 2.7 8 2. 0% 3.6 0 2. 00 3. 0% 4.8 7 2.3 2 5. 0% 0. 90 0. 3 5 Example 3 1 0. 0% majority "M. 5% 8. 0 5 4.4 3 1 . 0% 1.88 0.6 3 2. 0% 1.15 0.4 3 5. 0% 3.2 3 1.58 Example 3 3 0. 0 % 3.9 5 1.45 0. 5% 0.4 3 0. 0 5 1 . 0% 0.0 5 0.0 0 2. 0% 0.3 3 0. 1 8 5. 0% 0. 03 0. 00

※1 不溶性微粒子規格1 Ojum以上:S 1 2俚/mL, 2 5//m以上:蕊2個/m L ※2有多數褐色凝膠狀異物狀,其數無法測定 -47- 200900066 . 【表1 6】*1 Insoluble fine particle size 1 Ojum or more: S 1 2俚/mL, 2 5//m or more: 2 cores/m L *2 There are many brown gelatinous foreign substances, and the number cannot be measured -47- 200900066. Table 1 6]

檢體 濃甘油 80W5日後不溶性微粒子(β/mL·) 添加酿 1 0//m以上聚1 2 以上 *1 0. 0% 多數*2 多數*2 0. 1% 多數*2 0. 5% 12. 04 6. 8 6 實施例3 0 1. 0% 8. 7 1 5. 36 2. 0% 6. 9 0 4. 23 3. 0% 7. 07 3.9 4 5. 0% 4. 7 4 2. 48 1 0. 0% 7. 7 4 4.6 3 0. 0% 多數M 多數《 0. 5% 2. 8 6 1.46 1. 0% 4. 5 3 2. 11 實施例3 2 1 . 5% 2. 3 1 1.14 2. 0% 2. 2 4 0.9 6 3. 0% 2. 5 4 1 . 10 5. 0% 3. 16 1.63 10 0% 6. 1 2 4. 1 2 0. 0% 3. 9 5 1. 45 0. 5% 0. 9 0 0. 2 5 實施例3 4 1 . 0% 0. 2 0 0. 03 2· 0% 0. 35 0. 05 5. 0% 0. 6 0 0. 35 10 0% 0. 7 5 0. 28 不溶性微粒子规格1 0 m以上:各1 2個/m L. 2 5以上:S2個/mL 亲2有多數褐色凝膠狀異物狀,其數無法測定The sample is concentrated with glycerin 80W5 insoluble microparticles (β/mL·). Adding 1 0//m or more poly 1 2 or more *1 0. 0% Most *2 Most *2 0. 1% Most *2 0. 5% 12 04 6. 8 6 Example 3 0 1. 0% 8. 7 1 5. 36 2. 0% 6. 9 0 4. 23 3. 0% 7. 07 3.9 4 5. 0% 4. 7 4 2 48 1 0. 0% 7. 7 4 4.6 3 0. 0% Most M Most "0. 5% 2. 8 6 1.46 1. 0% 4. 5 3 2. 11 Example 3 2 1 . 5% 2 . 3 1 1.14 2. 0% 2. 2 4 0.9 6 3. 0% 2. 5 4 1 . 10 5. 0% 3. 16 1.63 10 0% 6. 1 2 4. 1 2 0. 0% 3. 9 5 1. 45 0. 5% 0. 9 0 0. 2 5 Example 3 4 1 . 0% 0. 2 0 0. 03 2· 0% 0. 35 0. 05 5. 0% 0. 6 0 0. 35 10 0% 0. 7 5 0. 28 Insoluble fine particles specifications 10 m or more: each 12 / m L. 2 5 or more: S2 / mL pro 2 has a large number of brown gelatinous foreign bodies, the number Unable to measure

[試驗例7] 將實施例31及3 2之製劑於8 0 °C保存5日’評價保存後 之類縁物質。類縁物質乃依以下所示HPLC條件測定。類 縁物質之測定結果如表1 6。其結果,確認因醇類之添加而 類縁物質量也減低。 HPLC條件; •檢出器:紫外吸光光度計(波長295nm)[Test Example 7] The preparations of Examples 31 and 32 were stored at 80 ° C for 5 days to evaluate the ruthenium-like substance after storage. The terpenoids were determined according to the HPLC conditions shown below. The measurement results of the terpenoids are shown in Table 16. As a result, it was confirmed that the quality of the steroids was also lowered due to the addition of alcohols. HPLC conditions; • Detector: UV spectrophotometer (wavelength 295 nm)

•柱:TSK gel ODS-80Ts •柱溫度:40°C •移動相:1-壬磺酸鈉及乙酸銨之0.05mol/L磷酸鹽緩衝液/ -48- 200900066• Column: TSK gel ODS-80Ts • Column temperature: 40 ° C • Mobile phase: 1-molar sodium sulfonate and ammonium acetate 0.05 mol / L phosphate buffer / -48- 200900066

乙腈混液(7 : 3)溶液 * 流量:約 0.9 m L / m i η •溶液注入量:5 // L fAcetonitrile mixed solution (7:3) solution * Flow rate: approx. 0.9 m L / m i η • Solution injection amount: 5 // L f

-49- 200900066 0% 3 2% 10‘ d 0% 2 8% 甘油添力卩_度 in d 實施例32 2. 0% [ 0. 2 7% 0% 2 9% r- d 5% 3 0% d 6 0% 2 7% in 〇 0% r- N csi 〇 實施例31 m i 1. 0% 0. 2 7% fO 5% 2 9% d O 0. 0% 0.4 6% 相對保持時間 類緣物質合計 -50- 200900066 【圖式簡單說明】 【第1圖】列示關於實施例4〜1 5之各處方以濾器濾集 之不溶性微粒子之狀況。0 :與對照例2同等,+1 :與對 照例2比較,若干之微粒子減少,+2 :與對照例2比較 ,微粒子減少,+3 :與對照例2比較,微粒子之減少較 大,+4 :與對照例2比較,微粒子之減少較大且微粒子 幾無認出。 【第2圖】列示於實施例29、31及33之處方之不溶性 Γ' 微粒子之狀況。 【第3圖】列示於實施例30、32及34之處方之不溶性 微粒子之狀況。 【主要元件符號說明】 ' ΪΕΕ。-49- 200900066 0% 3 2% 10' d 0% 2 8% glycerol 卩 卩 度 in d Example 32 2. 0% [ 0. 2 7% 0% 2 9% r- d 5% 3 0 % d 6 0% 2 7% in 〇0% r- N csi 〇 Example 31 mi 1. 0% 0. 2 7% fO 5% 2 9% d O 0. 0% 0.4 6% Relative retention time Substance total -50-200900066 [Simplified description of the drawings] [Fig. 1] shows the state of insoluble fine particles filtered by a filter in each of Examples 4 to 15. 0: same as Comparative Example 2, +1: Compared with Comparative Example 2, several microparticles were reduced, +2: compared with Comparative Example 2, microparticles were reduced, +3: compared with Comparative Example 2, the reduction of microparticles was large, + 4: Compared with Comparative Example 2, the reduction of the fine particles was large and the fine particles were not recognized. [Fig. 2] shows the state of insoluble Γ' microparticles at the positions of Examples 29, 31 and 33. [Fig. 3] The conditions of the insoluble microparticles shown in Examples 30, 32 and 34 are shown. [Main component symbol description] ' ΪΕΕ.

/INN -51 -/INN -51 -

Claims (1)

200900066 十、申請專利範圍: 1 · 一種水性製劑,內含喹喏酮化合物及醇。 2 .如申請專利範圍第1項之水性製劑,其中醇爲碳數爲 1〜6,係由1價、2價、或3價之脂肪族醇及苄醇而成之 群之醇選擇之醇。 3 ·如申請專利範圍第2項之水性製劑,其中醇爲乙醇、乙 二醇、丙二醇、甘油、或苄醇。 4.如申請專利範圍第1至3項中任一項之水性製劑,其中 (Ί 唾喏酮化合物爲如下式(1)化合物200900066 X. Patent application scope: 1 · An aqueous preparation containing a quinophthalone compound and an alcohol. 2. The aqueous preparation according to claim 1, wherein the alcohol is an alcohol having a carbon number of 1 to 6, which is an alcohol selected from the group consisting of a monovalent, a divalent or a trivalent aliphatic alcohol and a benzyl alcohol. . 3. An aqueous preparation according to claim 2, wherein the alcohol is ethanol, ethylene glycol, propylene glycol, glycerin, or benzyl alcohol. 4. The aqueous preparation according to any one of claims 1 to 3, wherein the oxime oxime compound is a compound of the following formula (1) [式中R1爲 碳數1〜6之烷基、 碳數2〜6之烯基、 碳數1~6之鹵烷基、 可有鹵原子取代之碳數3~6之環狀院基、 碳數1〜6之烷氧基、 碳數1〜6之烷胺基、 可有鹵原子、羥基、胺基、硝基、碳數1~6之院基、 或碳數1~6之烷氧基取代之芳基、或 可有鹵原子或碳數1~6之烷基取代之雜芳基; R2爲氫原子或碳數1~6之烷硫基;此R1與R2可包括 母核之一部分而一體化形成環狀構造,此環可含有硫原 -52- 200900066 子爲環之構成原子,此環更可有碳數i〜6之烷基爲取代 基; R3爲氫原子、胺基(此胺基可有甲醯基、碳數丨〜6之 院基或碳數2〜5之醯基取代)、硫醇基、鹵甲基、碳數 1〜6之院基、碳數2-6之烯基、碳數2〜6之炔基、或碳 數1〜6之烷氧基; A1爲氮原子或如下式(2)部分構造、[wherein R1 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, a cyclic group having 3 to 6 carbon atoms which may be substituted by a halogen atom, An alkoxy group having 1 to 6 carbon atoms, an alkylamino group having 1 to 6 carbon atoms, a halogen atom, a hydroxyl group, an amine group, a nitro group, a hospital group having 1 to 6 carbon atoms, or an alkyl group having 1 to 6 carbon atoms An aryl-substituted aryl group or a heteroaryl group which may have a halogen atom or an alkyl group having 1 to 6 carbon atoms; R 2 is a hydrogen atom or an alkylthio group having 1 to 6 carbon atoms; and R 1 and R 2 may include a mother nucleus a part of which is integrated to form a cyclic structure, and the ring may contain a constituent atom of a ring of sulfur-52-200900066, and the ring may have a substituent of a carbon number i to 6; R3 is a hydrogen atom, an amine Base (this amine group may have a mercapto group, a carbon number of 6~6 or a carbon number of 2 to 5 thiol), a thiol group, a halomethyl group, a carbon number of 1 to 6, a carbon number 2-6 alkenyl group, alkylene group having 2 to 6 carbon atoms, or alkoxy group having 1 to 6 carbon atoms; A1 is a nitrogen atom or a partial structure of the following formula (2), (式中X2爲氫原子、胺基(此胺基可有甲醯基、碳數 1〜6之院基或碳數2〜5之醯基取代)、鹵原子、氰基 '鹵 甲基、鹵甲氧基、碳數1〜6之烷基、碳數2〜6之烯基、 碳數2〜6之炔基、或碳數^6之烷氧基;此χ2與上述 R1可包括母核之一部分而一體化形成環狀構造,如此形 成之環此環可含有氧原子、氮原子、或硫原子爲環之構 成原子,此環更可有碳數1〜6之烷基爲取代基); Α2及Α3各相異爲氮原子或碳原子,但Ai、a2及Α3 與這些結合之碳原子形成如下部分構造(wherein X2 is a hydrogen atom or an amine group (the amine group may have a methyl group, a carbon number of 1 to 6 or a fluorenyl group having 2 to 5 carbon atoms), a halogen atom, a cyano 'halomethyl group, a halomethoxy group, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, or an alkoxy group having 6 or 6 carbon atoms; and the above R1 may include a mother One part of the core is integrated to form a cyclic structure, and the ring thus formed may contain an oxygen atom, a nitrogen atom, or a sulfur atom as a constituent atom of the ring, and the ring may have an alkyl group having 1 to 6 carbon atoms as a substituent. Α2 and Α3 are each a nitrogen atom or a carbon atom, but Ai, a2 and Α3 form a partial structure with these bonded carbon atoms. 现5U F部分構造Now 5U F part construction -53 - 200900066 χ1爲鹵原子或氫原子; Y爲氫原子、苯基、乙醯氧甲基、特戊醯氧甲基、乙 氧羰基、甲基吡啶基、二甲胺基乙基、5 -氫茚基、酞基 、5-烷基-2-氧-1,3-二咢茂-4-基甲基、3-乙醯氧基-2-氧 丁基、碳數1〜6之烷基、碳數2〜7之烷氧甲基、或由碳 數1〜6之伸烷基與苯基而構成之苯烷基; Z爲單環式、二環式、或三環式之雜環式取代基,此 雜環式取代基可飽和或部分飽和,可含有由氮原子、氧 原子及硫原子選擇之1以上之雜原子,更可爲雙環構造 或螺環狀構造,而可有由鹵原子、羥基、胺基、胺甲醯 基、碳數1〜6之烷基、碳數1〜6之鹵烷基、芳基、雜芳 基、碳數卜6之烷氧基、碳數1〜6之烷胺基、碳數1〜6 之烷硫基、及碳數1〜6之胺烷基而成之群選擇之1或2 以上之原子或基取代]。 5 . —種含有喹喏酮之水性製劑之安定化方法,其特徵爲於 含有喹喏酮化合物之水溶液添加醇。 6. 如申請專利範圍第5項之含有喹喏酮之水性製劑之安定 化方法,其中以抑制不溶性微粒子及/或類縁物質之生成 來安定化。 7. 如申請專利範圍第5或6項之含有喹喏酮之水性製劑之 安定化方法,其中醇爲碳數爲1〜6,而係由1價、2價 、或3價之脂肪族醇及苄醇而成之群之醇選擇之醇。 8. 如申請專利範圍第5至7項中任一項之含有喹喏酮之水 性製劑之安定化方法,其中醇爲乙醇、乙二醇、丙二醇 -54- 200900066 、甘油、或苄醇。 9.如申請專利範圍第5至8項中任一項之含有喹喏酮之水 性製劑之安定化方法,其中喹喏酮化合物爲如下式(1)化 合物-53 - 200900066 χ1 is a halogen atom or a hydrogen atom; Y is a hydrogen atom, a phenyl group, an ethoxymethyl group, a pentyloxymethyl group, an ethoxycarbonyl group, a methylpyridyl group, a dimethylaminoethyl group, and 5 -hydroindolyl, fluorenyl, 5-alkyl-2-oxo-1,3-dioxan-4-ylmethyl, 3-ethyloxy-2-oxobutyl, carbon number 1 to 6 An alkyl group, an alkoxymethyl group having 2 to 7 carbon atoms, or a phenylalkyl group having a C 1 to 6 alkyl group and a phenyl group; Z is a monocyclic, bicyclic or tricyclic ring. a heterocyclic substituent which may be saturated or partially saturated, may contain one or more hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, and may be a bicyclic structure or a spiro ring structure. There are a halogen atom, a hydroxyl group, an amine group, an amine carbenyl group, an alkyl group having 1 to 6 carbon atoms, a haloalkyl group having 1 to 6 carbon atoms, an aryl group, a heteroaryl group, an alkoxy group having a carbon number of 6, One or two or more atoms or groups of the alkyl group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, and an amine alkyl group having 1 to 6 carbon atoms are selected]. An method for stabilizing an aqueous preparation containing quinacridone, characterized in that an alcohol is added to an aqueous solution containing a quinophthalone compound. 6. The method for stabilizing an aqueous preparation containing quinacridone according to claim 5, wherein the method of inhibiting the formation of insoluble fine particles and/or terpenoids is stabilized. 7. The method for stabilizing an aqueous preparation containing quinacridone according to claim 5 or 6, wherein the alcohol is a monovalent, divalent or trivalent aliphatic alcohol having a carbon number of 1 to 6 An alcohol selected from the group consisting of benzyl alcohol. 8. The method for stabilizing an aqueous preparation containing quinacridone according to any one of claims 5 to 7, wherein the alcohol is ethanol, ethylene glycol, propylene glycol -54-200900066, glycerin, or benzyl alcohol. The method for the stabilization of an aqueous preparation containing quinacridone according to any one of claims 5 to 8, wherein the quinophthalone compound is a compound of the following formula (1) [式中R1爲 碳數1〜6之烷基、 碳數2~6之烯基、 碳數1~6之鹵院基、 可有鹵原子取代之碳數3 ~6之環狀烷基、 碳數1〜6之烷氧基、 碳數1〜6之烷胺基、 可有鹵原子、羥基、胺基、硝基、碳數1〜6之烷基、或 碳數1〜6之烷氧基取代之芳基、或 可有鹵原子或碳數1〜6之烷基取代之雜芳基; R2爲氫原子或碳數1〜6之烷硫基;此R1與R2可包括母 核之一部分而一體化形成環狀構造,此環可含有硫原子 爲環之構成原子,此環更可有碳數1〜6之烷基爲取代基 R3爲氫原子、胺基(此胺基可有甲醯基、碳數1〜6之烷 基或碳數2-5之醯基取代)、硫醇基、鹵甲基、碳數ι〜6 之烷基、碳數2〜6之烯基、碳數2〜6之炔基、或碳數 -55- 200900066 1〜6之院氧基; A1爲氮原子或如下式(2)部分構造[wherein R1 is an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, a halogen-based group having 1 to 6 carbon atoms, a cyclic alkyl group having 3 to 6 carbon atoms which may be substituted by a halogen atom, An alkoxy group having 1 to 6 carbon atoms, an alkylamino group having 1 to 6 carbon atoms, a halogen atom, a hydroxyl group, an amine group, a nitro group, an alkyl group having 1 to 6 carbon atoms, or an alkyl group having 1 to 6 carbon atoms An aryl-substituted aryl group or a heteroaryl group which may have a halogen atom or an alkyl group having 1 to 6 carbon atoms; R 2 is a hydrogen atom or an alkylthio group having 1 to 6 carbon atoms; and R 1 and R 2 may include a mother nucleus a part of which is integrated to form a cyclic structure, and the ring may contain a constituent atom in which a sulfur atom is a ring, and the ring may have an alkyl group having 1 to 6 carbon atoms as a substituent. R3 is a hydrogen atom or an amine group (this amine group may be a mercapto group, an alkyl group having 1 to 6 carbon atoms or a mercapto group having 2 to 5 carbon atoms, a thiol group, a halomethyl group, an alkyl group having 1 to 6 carbon atoms, and an alkenyl group having 2 to 6 carbon atoms An alkynyl group having a carbon number of 2 to 6, or an alkoxy group having a carbon number of -55 to 200900066 1 to 6; A1 being a nitrogen atom or a partial structure of the following formula (2) (式中X2爲氫原子、胺基(此胺基可有甲醯基、碳數 之烷基或碳數2~5之醯基取代)、鹵原子、氰基、鹵甲基 、鹵甲氧基、碳數1〜6之烷基、碳數2〜6之烯基、碳數 2~6之炔基、或碳數1〜6之烷氧基;此χ2與上述Ri可 包括母核之一部分而一體化形成環狀構造,如此形成之 環此環可含有氧原子、氮原子、或硫原子爲環之構成原 子’此環更可有碳數1〜6之院基爲取代基); A2及A3各相異爲氮原子或碳原子,但a1、a2及A3與 這些結合之碳原子形成如下部分構造(wherein X2 is a hydrogen atom or an amine group (the amine group may have a methyl group, a carbon number or an alkyl group having 2 to 5 carbon atoms), a halogen atom, a cyano group, a halomethyl group or a halogenated methoxy group. a base, an alkyl group having 1 to 6 carbon atoms, an alkenyl group having 2 to 6 carbon atoms, an alkynyl group having 2 to 6 carbon atoms, or an alkoxy group having 1 to 6 carbon atoms; and the above Ri and the above Ri may include a mother nucleus a part of which is integrated to form a ring-shaped structure, and the ring thus formed may contain an oxygen atom, a nitrogen atom, or a sulfur atom as a constituent atom of the ring, and the ring may have a substituent having a carbon number of 1 to 6 as a substituent; A2 and A3 are each a nitrogen atom or a carbon atom, but a1, a2 and A3 form a partial structure with these bonded carbon atoms. 或如下部分構造Or the following part of the structure R X1爲鹵原子或氫原子; γ爲氫原子、苯基、乙醯氧甲基、特戊醯氧甲基 '乙氧 羯基、甲基n比陡基、二甲胺基乙基、5 -氫節基、献基、 5-烷基·2-氧-I,3-二咢茂-4-基甲基、3·乙醯氧基·2_氧丁 基、碳數1〜6之烷基、碳數2〜7之烷氧甲基、或由碳數 -56- 200900066 1〜6之伸烷基與苯基而構成之苯烷基; Z爲單環式、二環式、或三環式之雜環式取代基,此雜 環式取代基可飽和或部分飽和,可含有由氮原子、氧原 子及硫原子選擇之1以上之雜原子’更可爲雙環構造或 螺環狀構造,而可有由画原子、羥基、胺基、胺甲醯基 、碳數1~6之院基、碳數1〜6之齒院基、方基、雑方基 、碳數1〜6之烷氧基、碳數1〜6之烷胺基、碳數1~6之 烷硫基、及碳數1~6之胺烷基而成之群選擇之1或2以 上之原子或基取代]。 -57-R X1 is a halogen atom or a hydrogen atom; γ is a hydrogen atom, a phenyl group, an acetoxymethyl group, a p-pentyloxymethyl 'ethoxylated oxime group, a methyl n-steep group, a dimethylaminoethyl group, 5 -Hydroxyl group, donor group, 5-alkyl-2-oxo-I,3-didecyl-4-ylmethyl, 3·ethoxycarbonyl·2-oxybutyl, carbon number 1~6 An alkyl group, an alkoxymethyl group having 2 to 7 carbon atoms, or a phenylalkyl group having a carbon number of -56 to 200900066 1 to 6 and a phenyl group; Z is a monocyclic ring, a bicyclic ring, or a tricyclic heterocyclic substituent which may be saturated or partially saturated, and may contain a hetero atom selected from a nitrogen atom, an oxygen atom and a sulfur atom, and may be a bicyclic structure or a spiro ring. Structure, but may have a picture of atoms, hydroxyl groups, amine groups, amine methyl sulfhydryl groups, a carbon number of 1 to 6, a carbon number of 1 to 6, a dental base, a square base, a square base, a carbon number of 1 to 6 One or more substituents of one or more selected from the group consisting of an alkoxy group, an alkylamino group having 1 to 6 carbon atoms, an alkylthio group having 1 to 6 carbon atoms, and an amine alkyl group having 1 to 6 carbon atoms ]. -57-
TW097109983A 2007-03-22 2008-03-21 Quinolone medical composition containing alcohols TW200900066A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007075013 2007-03-22

Publications (1)

Publication Number Publication Date
TW200900066A true TW200900066A (en) 2009-01-01

Family

ID=39765961

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097109983A TW200900066A (en) 2007-03-22 2008-03-21 Quinolone medical composition containing alcohols

Country Status (2)

Country Link
TW (1) TW200900066A (en)
WO (1) WO2008114861A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6099557B2 (en) * 2013-12-27 2017-03-22 富士フイルム株式会社 Injection solution preparation and method for producing the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61180771A (en) * 1985-01-05 1986-08-13 バイエル・アクチエンゲゼルシヤフト Basic prescription of quinolone carboxylic acid
DE3537761A1 (en) * 1985-10-24 1987-04-30 Bayer Ag INFUSION SOLUTIONS OF 1-CYCLOPROPYL-6-FLUOR-1,4-DIHYDRO-4-OXO-7- (1-PIPERAZINYL) -QUINOLINE-3-CARBONIC ACID
JPH0696533B2 (en) * 1987-01-14 1994-11-30 北陸製薬株式会社 Aqueous composition of quinolonecarboxylic acid
DE3831514A1 (en) * 1988-09-16 1990-03-22 Bayer Ag PH NEUTRAL WAESSED SOLUTIONS OF CHINOLO CARBON ACIDS
FR2681863B1 (en) * 1991-09-27 1995-02-03 Rhone Dpc Europ SOLUTION OF SPARFLOXACIN, ITS PREPARATION AND SALT CONSTITUTING IT.
JPH0782141A (en) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd Injection for animals
CA2293008A1 (en) * 1999-01-28 2000-07-28 Hong Qi Premixed alatrofloxacin injectable compositions
DE19937115A1 (en) * 1999-08-06 2001-02-08 Bayer Ag Aqueous drug formulation of moxifloxacin or salts thereof
JP3648132B2 (en) * 2000-06-19 2005-05-18 大正薬品工業株式会社 Quinolone antibacterial liquid preparation and its packaging

Also Published As

Publication number Publication date
WO2008114861A1 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
TWI730959B (en) Heterocyclic amides as kinase inhibitors
Paluch et al. Formation and physicochemical properties of crystalline and amorphous salts with different stoichiometries formed between ciprofloxacin and succinic acid
JP4789264B2 (en) Fasudil-containing preparation and method for improving its stability
CN104788427B (en) 3 (2 pyrimdinyl-amino) phenylacryloyl amine compounds and its application
KR101420315B1 (en) Pharmaceutical liquid composition
CA2786824C (en) Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
JPS6094910A (en) Lactate solution of piperazinyl-quinolone and piperazinyl-azaquinolone carboxylic acid
US20120208887A1 (en) Stable, liquid, ready-to-use ketoprofen formulations
TWI236372B (en) Formulation of substituted benzimidazoles
RU2013130224A (en) PHARMACEUTICAL COMPOSITIONS
TW200942240A (en) Aqueous pharmaceutical formulation
WO2006134877A1 (en) Injection
US8163747B2 (en) Acid addition salts, hydrates and polymorphs of 5-(2,4-dihydroxy-5-isopropyl-phenyl)-4-(4-morpholin-4-ylmethyl-phenyl)-isoxazole-3-carboxylic acid ethylamide and formulations comprising these forms
CA2441425A1 (en) Antipruritics
AU2007248949B2 (en) Parenteral formulation comprising proton pump inhibitor sterilized in its final container by ionizing radiation
JP6923122B2 (en) Poorly soluble complex or solvate thereof, drug composition and its application
TW200900066A (en) Quinolone medical composition containing alcohols
JP2001278788A (en) Stable liquid formulation containing allantoin
JP5535900B2 (en) Gatifloxacin-containing aqueous solution, method for producing the same, and method for inhibiting precipitation of the aqueous solution at low temperature storage and freezing and thawing
TWI327910B (en)
JPH0576929B2 (en)
CN102688189A (en) Lurasidone medicine composition and preparation method thereof
JP2000219628A (en) Previously mixed injectable composition of alatrofloxacin
WO2005070426A1 (en) Freeze-dried (-)-pantoprazole preparation and (-)-pantoprazole injection
JP6039849B1 (en) Aripiprazole-containing internal preparation